Sites of infection in neutropenic patients
\\n\\n
Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\\n\\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'IntechOpen is proud to announce that 179 of our authors have made the Clarivate™ Highly Cited Researchers List for 2020, ranking them among the top 1% most-cited.
\n\nThroughout the years, the list has named a total of 252 IntechOpen authors as Highly Cited. Of those researchers, 69 have been featured on the list multiple times.
\n\n\n\nReleased this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\n\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\n'}],latestNews:[{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"},{slug:"oiv-awards-recognizes-intechopen-s-editors-20201127",title:"OIV Awards Recognizes IntechOpen's Editors"},{slug:"intechopen-joins-crossref-s-initiative-for-open-abstracts-i4oa-to-boost-the-discovery-of-research-20201005",title:"IntechOpen joins Crossref's Initiative for Open Abstracts (I4OA) to Boost the Discovery of Research"},{slug:"intechopen-hits-milestone-5-000-open-access-books-published-20200908",title:"IntechOpen hits milestone: 5,000 Open Access books published!"},{slug:"intechopen-books-hosted-on-the-mathworks-book-program-20200819",title:"IntechOpen Books Hosted on the MathWorks Book Program"}]},book:{item:{type:"book",id:"463",leadTitle:null,fullTitle:"A Comprehensive Book on Autism Spectrum Disorders",title:"A Comprehensive Book on Autism Spectrum Disorders",subtitle:null,reviewType:"peer-reviewed",abstract:'The aim of the book is to serve for clinical, practical, basic and scholarly practices. In twentyfive chapters it covers the most important topics related to Autism Spectrum Disorders in the efficient way and aims to be useful for health professionals in training or clinicians seeking an update. Different people with autism can have very different symptoms. Autism is considered to be a "spectrum" disorder, a group of disorders with similar features. Some people may experience merely mild disturbances, while the others have very serious symptoms. This book is aimed to be used as a textbook for child and adolescent psychiatry fellowship training and will serve as a reference for practicing psychologists, child and adolescent psychiatrists, general psychiatrists, pediatricians, child neurologists, nurses, social workers and family physicians. A free access to the full-text electronic version of the book via Intech reading platform at http://www.intechweb.org is a great bonus.',isbn:null,printIsbn:"978-953-307-494-8",pdfIsbn:"978-953-51-4434-2",doi:"10.5772/975",price:139,priceEur:155,priceUsd:179,slug:"a-comprehensive-book-on-autism-spectrum-disorders",numberOfPages:490,isOpenForSubmission:!1,isInWos:1,hash:null,bookSignature:"Mohammad-Reza Mohammadi",publishedDate:"September 15th 2011",coverURL:"https://cdn.intechopen.com/books/images_new/463.jpg",numberOfDownloads:113886,numberOfWosCitations:19,numberOfCrossrefCitations:39,numberOfDimensionsCitations:128,hasAltmetrics:1,numberOfTotalCitations:186,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 20th 2010",dateEndSecondStepPublish:"November 17th 2010",dateEndThirdStepPublish:"March 24th 2011",dateEndFourthStepPublish:"April 23rd 2011",dateEndFifthStepPublish:"June 22nd 2011",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,8",editedByType:"Edited by",kuFlag:!1,editors:[{id:"62755",title:"Dr.",name:"Mohammad-Reza",middleName:null,surname:"Mohammadi",slug:"mohammad-reza-mohammadi",fullName:"Mohammad-Reza Mohammadi",profilePictureURL:"https://mts.intechopen.com/storage/users/62755/images/1662_n.jpg",biography:"Professor Mohammad-Reza Mohammadi works as a child and adolescent psychiatrist at Tehran University of Medical Sciences (TUMS), and is the chair of Psychiatry and Psychology Research Centre of Iran. He has authored more than 160 articles, 23 books, and few book chapters. He obtained a diploma in Child and Adolescent Psychiatry as well as M.Phil. at the University of London, 1996 and 1997; in Cognitive Behavior Therapy at Middle Sex Hospital, University College of London (UCL) 1998. He is the founder and the Editor-in-chief of Iranian Journal of Psychiatry (IJP). He is also a member of Editorial Boards of many Iranian and International journals. He established University of Welfare and Rehabilitation Sciences in 1992, and has been the Head of National Research Centre for Medical Sciences of Iran (2001-2005). His research interests include epidemiological and clinical trial, cognitive behavior therapy and spiritual psychotherapy.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Tehran University of Medical Sciences",institutionURL:null,country:{name:"Iran"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1061",title:"Psychiatry",slug:"mental-and-behavioural-disorders-and-diseases-of-the-nervous-system-psychiatry"}],chapters:[{id:"20029",title:"Language Assessment in Autism",doi:"10.5772/17412",slug:"language-assessment-in-autism",totalDownloads:9406,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Fernanda Dreux M.Fernandes, Cibelle A.H. Amato and Daniela R.Molini-Avejonas",downloadPdfUrl:"/chapter/pdf-download/20029",previewPdfUrl:"/chapter/pdf-preview/20029",authors:[{id:"28286",title:"Dr.",name:"Fernanda Dreux Miranda",surname:"Fernandes",slug:"fernanda-dreux-miranda-fernandes",fullName:"Fernanda Dreux Miranda Fernandes"},{id:"38598",title:"Dr.",name:"Cibelle",surname:"Amato",slug:"cibelle-amato",fullName:"Cibelle Amato"},{id:"38599",title:"Prof.",name:"Daniela",surname:"Molini-Avejonas",slug:"daniela-molini-avejonas",fullName:"Daniela Molini-Avejonas"}],corrections:null},{id:"20030",title:"Language Therapy with Children with Autism Spectrum Disorders",doi:"10.5772/20371",slug:"language-therapy-with-children-with-autism-spectrum-disorders",totalDownloads:4264,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Fernanda Dreux M.Fernandes, Daniela R.Molini-Avejonas and Cibelle A.H.Amato",downloadPdfUrl:"/chapter/pdf-download/20030",previewPdfUrl:"/chapter/pdf-preview/20030",authors:[{id:"28286",title:"Dr.",name:"Fernanda Dreux Miranda",surname:"Fernandes",slug:"fernanda-dreux-miranda-fernandes",fullName:"Fernanda Dreux Miranda Fernandes"},{id:"38598",title:"Dr.",name:"Cibelle",surname:"Amato",slug:"cibelle-amato",fullName:"Cibelle Amato"},{id:"38599",title:"Prof.",name:"Daniela",surname:"Molini-Avejonas",slug:"daniela-molini-avejonas",fullName:"Daniela Molini-Avejonas"}],corrections:null},{id:"20031",title:"Repetetive Extralinguistic, Prosodic and Linguistic Behavior in Autism Spectrum Disorders-High Functioning (ASD-HF)",doi:"10.5772/18595",slug:"repetetive-extralinguistic-prosodic-and-linguistic-behavior-in-autism-spectrum-disorders-high-functi",totalDownloads:2135,totalCrossrefCites:1,totalDimensionsCites:1,signatures:"Hila Green and Yishai Tobin",downloadPdfUrl:"/chapter/pdf-download/20031",previewPdfUrl:"/chapter/pdf-preview/20031",authors:[{id:"31964",title:"Dr.",name:"Yishai",surname:"Tobin",slug:"yishai-tobin",fullName:"Yishai Tobin"},{id:"43204",title:"Dr",name:"Hila",surname:"Green",slug:"hila-green",fullName:"Hila Green"}],corrections:null},{id:"20032",title:"Variability in Language and Reading in High-Functioning Autism",doi:"10.5772/17706",slug:"variability-in-language-and-reading-in-high-functioning-autism",totalDownloads:4777,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Cheryl Smith Gabig",downloadPdfUrl:"/chapter/pdf-download/20032",previewPdfUrl:"/chapter/pdf-preview/20032",authors:[{id:"29192",title:"Dr.",name:"Cheryl",surname:"Smith Gabig",slug:"cheryl-smith-gabig",fullName:"Cheryl Smith Gabig"}],corrections:null},{id:"20033",title:"Parenting Stress in Mothers and Fathers of Children with Autism Spectrum Disorders",doi:"10.5772/18507",slug:"parenting-stress-in-mothers-and-fathers-of-children-with-autism-spectrum-disorders",totalDownloads:18429,totalCrossrefCites:12,totalDimensionsCites:24,signatures:"Ewa Pisula",downloadPdfUrl:"/chapter/pdf-download/20033",previewPdfUrl:"/chapter/pdf-preview/20033",authors:[{id:"31714",title:"Prof.",name:"Ewa",surname:"Pisula",slug:"ewa-pisula",fullName:"Ewa Pisula"}],corrections:null},{id:"20034",title:"Psychological Adaptation in Parents of Children with Autism Spectrum Disorders",doi:"10.5772/18705",slug:"psychological-adaptation-in-parents-of-children-with-autism-spectrum-disorders",totalDownloads:5453,totalCrossrefCites:4,totalDimensionsCites:7,signatures:"Pilar Pozo, Encarnación Sarriá and Ángeles Brioso",downloadPdfUrl:"/chapter/pdf-download/20034",previewPdfUrl:"/chapter/pdf-preview/20034",authors:[{id:"32306",title:"Dr.",name:"Encarnacion",surname:"Sarria",slug:"encarnacion-sarria",fullName:"Encarnacion Sarria"},{id:"44602",title:"Dr.",name:"Pilar",surname:"Pozo",slug:"pilar-pozo",fullName:"Pilar Pozo"},{id:"44603",title:"MSc.",name:"Angeles",surname:"Brioso",slug:"angeles-brioso",fullName:"Angeles Brioso"}],corrections:null},{id:"20035",title:"A Comparative Study on Self Perceived Health and Quality of Life of Parents of Children with Autism Spectrum Disorders and Parents of Non Disabled Children in Croatia",doi:"10.5772/17368",slug:"a-comparative-study-on-self-perceived-health-and-quality-of-life-of-parents-of-children-with-autism-",totalDownloads:1791,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Tomislav Benjak, Gorka Vuletić Mavrinac,\nIvana Pavić Šimetin and Branko Kolarić",downloadPdfUrl:"/chapter/pdf-download/20035",previewPdfUrl:"/chapter/pdf-preview/20035",authors:[{id:"28139",title:"Dr.",name:"Tomislav",surname:"Benjak",slug:"tomislav-benjak",fullName:"Tomislav Benjak"},{id:"32794",title:"Dr.",name:"Gorka",surname:"Vuletic",slug:"gorka-vuletic",fullName:"Gorka Vuletic"},{id:"32795",title:"Dr.",name:"Ivana",surname:"Pavić Šimetin",slug:"ivana-pavic-simetin",fullName:"Ivana Pavić Šimetin"},{id:"77802",title:"Dr.",name:"Branko",surname:"Kolarić",slug:"branko-kolaric",fullName:"Branko Kolarić"}],corrections:null},{id:"20036",title:"Cross Cultural Variation in the Neurodevelopmental Assessment of Children – The Cultural and Neurological to 2nd Language Acquisition and Children with Autism",doi:"10.5772/19138",slug:"cross-cultural-variation-in-the-neurodevelopmental-assessment-of-children-the-cultural-and-neurologi",totalDownloads:3314,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Karen Mendez, Karen M, Levy, Marley Nelms, Dayna Hoff, Jean M. Novak and Michael L. Levy",downloadPdfUrl:"/chapter/pdf-download/20036",previewPdfUrl:"/chapter/pdf-preview/20036",authors:[{id:"33790",title:"Dr.",name:"Michael",surname:"Levy",slug:"michael-levy",fullName:"Michael Levy"},{id:"45556",title:"Prof.",name:"Jean",surname:"Novak",slug:"jean-novak",fullName:"Jean Novak"},{id:"45557",title:"BSc.",name:"Dayna",surname:"Hoff",slug:"dayna-hoff",fullName:"Dayna Hoff"}],corrections:null},{id:"20037",title:"Autism Spectrum Disorders in Iran",doi:"10.5772/38965",slug:"autism-spectrum-disorders-in-iran",totalDownloads:3183,totalCrossrefCites:0,totalDimensionsCites:3,signatures:"Mohammad-Reza Mohammadi, Maryam Salmanian and Shahin Akhondzadeh",downloadPdfUrl:"/chapter/pdf-download/20037",previewPdfUrl:"/chapter/pdf-preview/20037",authors:[{id:"62755",title:"Dr.",name:"Mohammad-Reza",surname:"Mohammadi",slug:"mohammad-reza-mohammadi",fullName:"Mohammad-Reza Mohammadi"},{id:"136676",title:"Prof.",name:"Maryam",surname:"Salmanian",slug:"maryam-salmanian",fullName:"Maryam Salmanian"},{id:"136677",title:"Dr.",name:"Shahin",surname:"Akhondzadeh",slug:"shahin-akhondzadeh",fullName:"Shahin Akhondzadeh"}],corrections:null},{id:"20038",title:"Autism Spectrum Disorders in Africa",doi:"10.5772/17469",slug:"autism-spectrum-disorders-in-africa",totalDownloads:7106,totalCrossrefCites:1,totalDimensionsCites:7,signatures:"Muideen O. Bakare and Kerim M. Munir",downloadPdfUrl:"/chapter/pdf-download/20038",previewPdfUrl:"/chapter/pdf-preview/20038",authors:[{id:"28435",title:"Dr.",name:"Muideen",surname:"Bakare",slug:"muideen-bakare",fullName:"Muideen Bakare"},{id:"74919",title:"Prof.",name:"Kerim",surname:"Munir",slug:"kerim-munir",fullName:"Kerim Munir"}],corrections:null},{id:"20039",title:"Sleep Concerns and Disorders in Children with an Autistic Spectrum Disorder (ASD)",doi:"10.5772/17381",slug:"sleep-concerns-and-disorders-in-children-with-an-autistic-spectrum-disorder-asd-",totalDownloads:1738,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Oreste Battisti",downloadPdfUrl:"/chapter/pdf-download/20039",previewPdfUrl:"/chapter/pdf-preview/20039",authors:[{id:"28175",title:"Prof.",name:"Oreste",surname:"Battisti",slug:"oreste-battisti",fullName:"Oreste Battisti"}],corrections:null},{id:"20040",title:"Sexual Abuse in Autistic Children as a Risk Factor of Developing of Schizophrenia",doi:"10.5772/17416",slug:"sexual-abuse-in-autistic-children-as-a-risk-factor-of-developing-of-schizophrenia",totalDownloads:2282,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Piotr W. Gorczyca, Agnieszka Kapinos-Gorczyca, Katarzyna Ziora and Joanna Oświęcimska",downloadPdfUrl:"/chapter/pdf-download/20040",previewPdfUrl:"/chapter/pdf-preview/20040",authors:[{id:"28292",title:"Dr.",name:"Piotr",surname:"Gorczyca",slug:"piotr-gorczyca",fullName:"Piotr Gorczyca"},{id:"41633",title:"Dr.",name:"Agnieszka",surname:"Kapinos-Gorczyca",slug:"agnieszka-kapinos-gorczyca",fullName:"Agnieszka Kapinos-Gorczyca"},{id:"41634",title:"Dr.",name:"Katarzyna",surname:"Ziora",slug:"katarzyna-ziora",fullName:"Katarzyna Ziora"},{id:"41635",title:"Dr.",name:"Joanna",surname:"Oświęcimska",slug:"joanna-oswiecimska",fullName:"Joanna Oświęcimska"}],corrections:null},{id:"20041",title:"Creativity Psychosis Autism and the Social Brain",doi:"10.5772/17439",slug:"creativity-psychosis-autism-and-the-social-brain",totalDownloads:3726,totalCrossrefCites:3,totalDimensionsCites:3,signatures:"Michael Fitzgerald",downloadPdfUrl:"/chapter/pdf-download/20041",previewPdfUrl:"/chapter/pdf-preview/20041",authors:[{id:"28359",title:"Prof.",name:"Michael",surname:"Fitzgerald",slug:"michael-fitzgerald",fullName:"Michael Fitzgerald"}],corrections:null},{id:"20042",title:"Psychiatric and Occupational Histories in Families of Children with Autism",doi:"10.5772/18508",slug:"psychiatric-and-occupational-histories-in-families-of-children-with-autism",totalDownloads:1966,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"G. Robert DeLong, Marie MacDonald and Vidya Krishnamurthy",downloadPdfUrl:"/chapter/pdf-download/20042",previewPdfUrl:"/chapter/pdf-preview/20042",authors:[{id:"31715",title:"Prof.",name:"G. Robert",surname:"DeLong",slug:"g.-robert-delong",fullName:"G. Robert DeLong"},{id:"136674",title:"Dr.",name:"Marie",surname:"McDonald",slug:"marie-mcdonald",fullName:"Marie McDonald"},{id:"136675",title:"Dr.",name:"Vidya",surname:"Krishnamurthy",slug:"vidya-krishnamurthy",fullName:"Vidya Krishnamurthy"}],corrections:null},{id:"20043",title:"Moral Judgment in Autism",doi:"10.5772/17566",slug:"moral-judgment-in-autism",totalDownloads:3390,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Hirotoshi Hiraishi",downloadPdfUrl:"/chapter/pdf-download/20043",previewPdfUrl:"/chapter/pdf-preview/20043",authors:[{id:"28718",title:"Mr.",name:"Hirotoshi",surname:"Hiraishi",slug:"hirotoshi-hiraishi",fullName:"Hirotoshi Hiraishi"}],corrections:null},{id:"20044",title:"Autism Spectrum Disorders and the Criminal Law",doi:"10.5772/17703",slug:"autism-spectrum-disorders-and-the-criminal-law",totalDownloads:7851,totalCrossrefCites:5,totalDimensionsCites:10,signatures:"Ian Freckelton",downloadPdfUrl:"/chapter/pdf-download/20044",previewPdfUrl:"/chapter/pdf-preview/20044",authors:[{id:"29183",title:"Prof.",name:"Ian",surname:"Freckelton",slug:"ian-freckelton",fullName:"Ian Freckelton"}],corrections:null},{id:"20045",title:"The Financial Side of Autism: Private and Public Costs",doi:"10.5772/18588",slug:"the-financial-side-of-autism-private-and-public-costs",totalDownloads:4615,totalCrossrefCites:1,totalDimensionsCites:17,signatures:"Deanna L. Sharpe and Dana L. Baker",downloadPdfUrl:"/chapter/pdf-download/20045",previewPdfUrl:"/chapter/pdf-preview/20045",authors:[{id:"31943",title:"Dr.",name:"Deanna",surname:"Sharpe",slug:"deanna-sharpe",fullName:"Deanna Sharpe"},{id:"45645",title:"Prof.",name:"Dana",surname:"Baker",slug:"dana-baker",fullName:"Dana Baker"}],corrections:null},{id:"20046",title:"Early Behavioural Alterations in Mouse Models of Autism Spectrum Disorders: A Step Forward Towards the Discovery of New Therapeutic Approaches",doi:"10.5772/23644",slug:"early-behavioural-alterations-in-mouse-models-of-autism-spectrum-disorders-a-step-forward-towards-th",totalDownloads:2779,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Bianca De Filippis, Emilia Romano and Giovanni Laviola",downloadPdfUrl:"/chapter/pdf-download/20046",previewPdfUrl:"/chapter/pdf-preview/20046",authors:[{id:"52943",title:"Dr.",name:"Giovanni",surname:"Laviola",slug:"giovanni-laviola",fullName:"Giovanni Laviola"},{id:"117620",title:"Dr.",name:"Bianca",surname:"De Filippis",slug:"bianca-de-filippis",fullName:"Bianca De Filippis"},{id:"117621",title:"Ms.",name:"Emilia",surname:"Romano",slug:"emilia-romano",fullName:"Emilia Romano"}],corrections:null},{id:"20047",title:"Impaired Sociability of the Balb/c Mouse, an Animal Model of Autism Spectrum Disorders, is Attenuated by NMDA Receptor Agonist Interventions: Clinical Implications",doi:"10.5772/18613",slug:"impaired-sociability-of-the-balb-c-mouse-an-animal-model-of-autism-spectrum-disorders-is-attenuated-",totalDownloads:2338,totalCrossrefCites:0,totalDimensionsCites:9,signatures:"Stephen I. Deutsch, Jessica A. Burket, Maria R. Urbano, Amy L. Herndon and Erin E. Winebarger",downloadPdfUrl:"/chapter/pdf-download/20047",previewPdfUrl:"/chapter/pdf-preview/20047",authors:[{id:"32007",title:"Prof.",name:"Stephen",surname:"Deutsch",slug:"stephen-deutsch",fullName:"Stephen Deutsch"},{id:"41979",title:"Ms.",name:"Jessica",surname:"Burket",slug:"jessica-burket",fullName:"Jessica Burket"},{id:"41980",title:"Prof.",name:"Maria",surname:"Urbano",slug:"maria-urbano",fullName:"Maria Urbano"},{id:"41982",title:"Ms.",name:"Amy",surname:"Herndon",slug:"amy-herndon",fullName:"Amy Herndon"},{id:"111872",title:"Ms.",name:"Erin",surname:"Winebarger",slug:"erin-winebarger",fullName:"Erin Winebarger"}],corrections:null},{id:"20048",title:"Sensory Motor Development in Autism",doi:"10.5772/17456",slug:"sensory-motor-development-in-autism",totalDownloads:10085,totalCrossrefCites:1,totalDimensionsCites:2,signatures:"Yesim Fazlioglu and M. Oguz Gunsen",downloadPdfUrl:"/chapter/pdf-download/20048",previewPdfUrl:"/chapter/pdf-preview/20048",authors:[{id:"28406",title:"Prof.",name:"Yesim",surname:"Fazlioglu",slug:"yesim-fazlioglu",fullName:"Yesim Fazlioglu"},{id:"75192",title:"Mr.",name:"Oguz",surname:"Gunsen",slug:"oguz-gunsen",fullName:"Oguz Gunsen"}],corrections:null},{id:"20049",title:"The Relationship Between Visual Perspective Taking and Imitation Impairments in Children with Autism",doi:"10.5772/19717",slug:"the-relationship-between-visual-perspective-taking-and-imitation-impairments-in-children-with-autism",totalDownloads:2270,totalCrossrefCites:3,totalDimensionsCites:5,signatures:"Yue Yu, Yanjie Su and Raymond Chan",downloadPdfUrl:"/chapter/pdf-download/20049",previewPdfUrl:"/chapter/pdf-preview/20049",authors:[{id:"35954",title:"Prof.",name:"Raymond",surname:"Chan",slug:"raymond-chan",fullName:"Raymond Chan"},{id:"38950",title:"Mr",name:"Yue",surname:"Yu",slug:"yue-yu",fullName:"Yue Yu"},{id:"38951",title:"Prof.",name:"Yanjie",surname:"Su",slug:"yanjie-su",fullName:"Yanjie Su"}],corrections:null},{id:"20050",title:"Embodied Conversational Agents for Education in Autism",doi:"10.5772/18688",slug:"embodied-conversational-agents-for-education-in-autism",totalDownloads:2360,totalCrossrefCites:3,totalDimensionsCites:4,signatures:"Marissa Milne, Martin Luerssen, Trent Lewis, Richard Leibbrandt and David Powers",downloadPdfUrl:"/chapter/pdf-download/20050",previewPdfUrl:"/chapter/pdf-preview/20050",authors:[{id:"3276",title:"Dr.",name:"Martin",surname:"Luerssen",slug:"martin-luerssen",fullName:"Martin Luerssen"},{id:"32252",title:"Ms",name:"Marissa",surname:"Milne",slug:"marissa-milne",fullName:"Marissa Milne"},{id:"45683",title:"Dr.",name:"Trent",surname:"Lewis",slug:"trent-lewis",fullName:"Trent Lewis"},{id:"45684",title:"Dr.",name:"Richard",surname:"Leibbrandt",slug:"richard-leibbrandt",fullName:"Richard Leibbrandt"},{id:"45685",title:"Prof.",name:"David",surname:"Powers",slug:"david-powers",fullName:"David Powers"}],corrections:null},{id:"20051",title:"Statistical Analysis of Textual Data from Corpora of Written Communication – New Results from an Italian Interdisciplinary Research Program (EASIEST)",doi:"10.5772/18643",slug:"statistical-analysis-of-textual-data-from-corpora-of-written-communication-new-results-from-an-itali",totalDownloads:1994,totalCrossrefCites:0,totalDimensionsCites:4,signatures:"Lorenzo Bernardi and Arjuna Tuzzi",downloadPdfUrl:"/chapter/pdf-download/20051",previewPdfUrl:"/chapter/pdf-preview/20051",authors:[{id:"32097",title:"Prof.",name:"Arjuna",surname:"Tuzzi",slug:"arjuna-tuzzi",fullName:"Arjuna Tuzzi"},{id:"42412",title:"Prof.",name:"Lorenzo",surname:"Bernardi",slug:"lorenzo-bernardi",fullName:"Lorenzo Bernardi"}],corrections:null},{id:"20052",title:"The Body of the Autistic Child: An Integrated Approach",doi:"10.5772/20527",slug:"the-body-of-the-autistic-child-an-integrated-approach",totalDownloads:2561,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Fabien Joly",downloadPdfUrl:"/chapter/pdf-download/20052",previewPdfUrl:"/chapter/pdf-preview/20052",authors:[{id:"39352",title:"Dr.",name:"Fabien",surname:"JOLY",slug:"fabien-joly",fullName:"Fabien JOLY"}],corrections:null},{id:"20053",title:"Transition to Adulthood for High-Functioning Individuals with Autism Spectrum Disorders",doi:"10.5772/21506",slug:"transition-to-adulthood-for-high-functioning-individuals-with-autism-spectrum-disorders",totalDownloads:4106,totalCrossrefCites:4,totalDimensionsCites:23,signatures:"Steven K. Kapp, Alexander Gantman and Elizabeth A. Laugeson",downloadPdfUrl:"/chapter/pdf-download/20053",previewPdfUrl:"/chapter/pdf-preview/20053",authors:[{id:"43405",title:"Dr",name:"Elizabeth",surname:"Laugeson",slug:"elizabeth-laugeson",fullName:"Elizabeth Laugeson"},{id:"46932",title:"Mr.",name:"Steven",surname:"Kapp",slug:"steven-kapp",fullName:"Steven Kapp"},{id:"46933",title:"Dr.",name:"Alexander",surname:"Gantman",slug:"alexander-gantman",fullName:"Alexander Gantman"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"510",title:"Anxiety Disorders",subtitle:null,isOpenForSubmission:!1,hash:"183445801a9be3bfbce31fe9752ad3db",slug:"anxiety-disorders",bookSignature:"Vladimir Kalinin",coverURL:"https://cdn.intechopen.com/books/images_new/510.jpg",editedByType:"Edited by",editors:[{id:"31572",title:"Prof.",name:"Vladimir",surname:"Kalinin",slug:"vladimir-kalinin",fullName:"Vladimir Kalinin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"511",title:"Different Views of Anxiety Disorders",subtitle:null,isOpenForSubmission:!1,hash:"67c7072e43934bc5f7424204e0b70aa1",slug:"different-views-of-anxiety-disorders",bookSignature:"Salih Selek",coverURL:"https://cdn.intechopen.com/books/images_new/511.jpg",editedByType:"Edited by",editors:[{id:"33081",title:"Dr.",name:"Salih",surname:"Selek",slug:"salih-selek",fullName:"Salih Selek"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"223",title:"Autism Spectrum Disorders",subtitle:"From Genes to Environment",isOpenForSubmission:!1,hash:"b0f16213bb2d326764042954eb334d26",slug:"autism-spectrum-disorders-from-genes-to-environment",bookSignature:"Tim Williams",coverURL:"https://cdn.intechopen.com/books/images_new/223.jpg",editedByType:"Edited by",editors:[{id:"41876",title:"Prof.",name:"Tim",surname:"Williams",slug:"tim-williams",fullName:"Tim Williams"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3515",title:"Attention Deficit Hyperactivity Disorder in Children and Adolescents",subtitle:null,isOpenForSubmission:!1,hash:"25e76e7e9ad2a9da50530c3c68292feb",slug:"attention-deficit-hyperactivity-disorder-in-children-and-adolescents",bookSignature:"Somnath Banerjee",coverURL:"https://cdn.intechopen.com/books/images_new/3515.jpg",editedByType:"Edited by",editors:[{id:"73771",title:"Dr.",name:"Somnath",surname:"Banerjee",slug:"somnath-banerjee",fullName:"Somnath Banerjee"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4651",title:"A Fresh Look at Anxiety Disorders",subtitle:null,isOpenForSubmission:!1,hash:"8f18ff3698fbd7584a3da8a3e4916fba",slug:"a-fresh-look-at-anxiety-disorders",bookSignature:"Federico Durbano",coverURL:"https://cdn.intechopen.com/books/images_new/4651.jpg",editedByType:"Edited by",editors:[{id:"157077",title:"Dr.",name:"Federico",surname:"Durbano",slug:"federico-durbano",fullName:"Federico Durbano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"282",title:"New Insights into the Prevention and Treatment of Bulimia Nervosa",subtitle:null,isOpenForSubmission:!1,hash:"3544d2f89235668f1ee9883bb6c9dd66",slug:"new-insights-into-the-prevention-and-treatment-of-bulimia-nervosa",bookSignature:"Phillipa Hay",coverURL:"https://cdn.intechopen.com/books/images_new/282.jpg",editedByType:"Edited by",editors:[{id:"34283",title:"Prof.",name:"Phillipa",surname:"Hay",slug:"phillipa-hay",fullName:"Phillipa Hay"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"236",title:"Anxiety and Related Disorders",subtitle:null,isOpenForSubmission:!1,hash:"8803638bd81a7c2d3788846bdf14df5b",slug:"anxiety-and-related-disorders",bookSignature:"Ágnes Szirmai",coverURL:"https://cdn.intechopen.com/books/images_new/236.jpg",editedByType:"Edited by",editors:[{id:"52939",title:"Dr.",name:"Ágnes",surname:"Szirmai",slug:"agnes-szirmai",fullName:"Ágnes Szirmai"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7983",title:"Psychosomatic Medicine",subtitle:null,isOpenForSubmission:!1,hash:"4eabb8ae6669b096f822a3ebd57ef59d",slug:"psychosomatic-medicine",bookSignature:"Ignacio Jáuregui Lobera",coverURL:"https://cdn.intechopen.com/books/images_new/7983.jpg",editedByType:"Edited by",editors:[{id:"55769",title:"Prof.",name:"Ignacio",surname:"Jáuregui Lobera",slug:"ignacio-jauregui-lobera",fullName:"Ignacio Jáuregui Lobera"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8781",title:"Weight Management",subtitle:null,isOpenForSubmission:!1,hash:"865bbf7988bae3fdb09bf58d6e6a6cd5",slug:"weight-management",bookSignature:"Hubertus Himmerich",coverURL:"https://cdn.intechopen.com/books/images_new/8781.jpg",editedByType:"Edited by",editors:[{id:"231568",title:"Dr.",name:"Hubertus",surname:"Himmerich",slug:"hubertus-himmerich",fullName:"Hubertus Himmerich"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7150",title:"Psychopathology",subtitle:"An International and Interdisciplinary Perspective",isOpenForSubmission:!1,hash:"20069c97d42c17e629d5c581c18bc656",slug:"psychopathology-an-international-and-interdisciplinary-perspective",bookSignature:"Robert Woolfolk, Lesley Allen, Federico Durbano and Floriana Irtelli",coverURL:"https://cdn.intechopen.com/books/images_new/7150.jpg",editedByType:"Edited by",editors:[{id:"67877",title:"Dr.",name:"Robert",surname:"Woolfolk",slug:"robert-woolfolk",fullName:"Robert Woolfolk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"67322",slug:"corrigendum-to-sexual-dysfunction-in-patients-with-systemic-sclerosis",title:"Corrigendum to: Sexual Dysfunction in Patients with Systemic Sclerosis",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/67322.pdf",downloadPdfUrl:"/chapter/pdf-download/67322",previewPdfUrl:"/chapter/pdf-preview/67322",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/67322",risUrl:"/chapter/ris/67322",chapter:{id:"66966",slug:"sexual-dysfunction-in-patients-with-systemic-sclerosis",signatures:"Barbora Heřmánková",dateSubmitted:"July 16th 2018",dateReviewed:"April 5th 2019",datePrePublished:"May 3rd 2019",datePublished:null,book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null}},chapter:{id:"66966",slug:"sexual-dysfunction-in-patients-with-systemic-sclerosis",signatures:"Barbora Heřmánková",dateSubmitted:"July 16th 2018",dateReviewed:"April 5th 2019",datePrePublished:"May 3rd 2019",datePublished:null,book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null},book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"8032",leadTitle:null,title:"Staphylococcus and Streptococcus",subtitle:null,reviewType:"peer-reviewed",abstract:"Staphylococcus spp. and Streptococcus spp. have not only got pathogenic isolates, but also non-pathogenic isolates. Staphylococcus spp. and Streptococcus spp. that are Gram positive cocci are the main pathogens in several infections. Virulence factors such as usual and unusual surface proteins encoded by resistance genes are the main causes of pathogenesis. Multidrug-resistant pathogens that are the main causes of morbidity and mortality worldwide have the ability to synthesize a number of destructive enzymes encoded by resistance genes such as ?-lactamases. Resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Group A, and Group B Streptococcus have emerged throughout the world. To eliminate these resistant pathogens that cause untreatable, acute, and chronic infections, different new antimicrobials must be developed and used. The goal of this book is to provide the latest information about the above topics.",isbn:"978-1-78984-473-3",printIsbn:"978-1-78984-472-6",pdfIsbn:"978-1-78985-941-6",doi:"10.5772/intechopen.77863",price:119,priceEur:129,priceUsd:155,slug:"staphylococcus-and-streptococcus",numberOfPages:120,isOpenForSubmission:!1,hash:"b9ddbf132ac8ea9d2a7613836e5a27ca",bookSignature:"Sahra Kırmusaoğlu",publishedDate:"March 11th 2020",coverURL:"https://cdn.intechopen.com/books/images_new/8032.jpg",keywords:null,numberOfDownloads:2489,numberOfWosCitations:0,numberOfCrossrefCitations:1,numberOfDimensionsCitations:1,numberOfTotalCitations:2,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 24th 2018",dateEndSecondStepPublish:"January 29th 2019",dateEndThirdStepPublish:"March 30th 2019",dateEndFourthStepPublish:"June 18th 2019",dateEndFifthStepPublish:"August 17th 2019",remainingDaysToSecondStep:"2 years",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:"Edited by",kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"179460",title:"Dr.",name:"Sahra",middleName:null,surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu",profilePictureURL:"https://mts.intechopen.com/storage/users/179460/images/system/179460.jpeg",biography:"Dr. Kırmusaoğlu, PhD, is an assistant professor of Microbiology\nat the Department of Molecular Biology and Genetics, T.C. Haliç\nUniversity. She specialized in Microbiology at Abant Izzet Baysal\nUniversity (Biology Department), Turkey. Her previous experience\nincludes laboratory manager at microbiology laboratories in several\nresearch and private hospitals. Throughout her career, she collaborated\nwith academicians/researchers from Abant Izzate Baysal University (AIBU), Middle East Technical University (METU), and Istanbul\nUniversity Cerrahpaşa Faculty of Medicine, and has participated in various research projects.\nDr. Kırmusaoğlu’s research interests include medical microbiology, pathogenic bacteria, bacterial biofilms, antibiofilm and antibacterial activity, bacterial drug resistance, pathogen–host interactions, pathogenesis, molecular microbiology, and microbiota. She has published several international research articles, books, book chapters, and congress proceedings.\nShe is also the editor of Disinfection, Bacterial Pathogenesis and Antibacterial Control,\nand Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods\npublished by IntechOpen. In addition to these, she wrote the book Genel Biyoloji Laboratuvar\nKılavuzu (General Biology Laboratory Manual) published by Hipokrat Publisher.\nShe has contributed to a chapter translation of the book Sherris Medical Microbiology\nby Ryan et al. as one of the translation authors of Sherris Tıbbi Mikrobiyoloji, which is a\nTurkish translated book edited by Prof. Dr. Dürdal Us and Prof. Dr. Ahmet Başustaoğlu.",institutionString:"Haliç University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"6",totalChapterViews:"0",totalEditedBooks:"5",institution:{name:"Haliç University",institutionURL:null,country:{name:"Turkey"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"409",title:"Bacteriology",slug:"biochemistry-genetics-and-molecular-biology-microbiology-bacteriology"}],chapters:[{id:"70748",title:"Introductory Chapter: An Overview of the Genus Staphylococcus and Streptococcus",slug:"introductory-chapter-an-overview-of-the-genus-em-staphylococcus-em-and-em-streptococcus-em-",totalDownloads:273,totalCrossrefCites:0,authors:[{id:"179460",title:"Dr.",name:"Sahra",surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu"}]},{id:"66603",title:"Virulence Factors of Streptococcus mutans Related to Dental Caries",slug:"virulence-factors-of-em-streptococcus-mutans-em-related-to-dental-caries",totalDownloads:384,totalCrossrefCites:0,authors:[{id:"282054",title:"Ph.D.",name:"María Alejandra",surname:"Bojanich",slug:"maria-alejandra-bojanich",fullName:"María Alejandra Bojanich"},{id:"292367",title:"Mr.",name:"Mariano Daniel",surname:"Orlietti",slug:"mariano-daniel-orlietti",fullName:"Mariano Daniel Orlietti"}]},{id:"68220",title:"Toward Better Understanding on How Group A Streptococcus Manipulates Human Fibrinolytic System",slug:"toward-better-understanding-on-how-group-a-em-streptococcus-em-manipulates-human-fibrinolytic-system",totalDownloads:240,totalCrossrefCites:0,authors:[{id:"290636",title:"Dr.",name:"Ruby",surname:"Law",slug:"ruby-law",fullName:"Ruby Law"},{id:"300264",title:"Dr.",name:"Adam J.",surname:"Quek",slug:"adam-j.-quek",fullName:"Adam J. Quek"},{id:"300265",title:"Prof.",name:"James C.",surname:"Whisstock",slug:"james-c.-whisstock",fullName:"James C. Whisstock"}]},{id:"70554",title:"Cell Surface and Cytosolic Proteins of Group B Streptococcus Adding New Dimensions in Its Colonization and Pathogenesis",slug:"cell-surface-and-cytosolic-proteins-of-group-b-streptococcus-adding-new-dimensions-in-its-colonizati",totalDownloads:223,totalCrossrefCites:0,authors:[{id:"287626",title:"Dr.",name:"Manju",surname:"Pai",slug:"manju-pai",fullName:"Manju Pai"},{id:"295422",title:"Dr.",name:"Venkatesh",surname:"S Pai",slug:"venkatesh-s-pai",fullName:"Venkatesh S Pai"},{id:"295423",title:"Prof.",name:"Pratima",surname:"Gupta",slug:"pratima-gupta",fullName:"Pratima Gupta"},{id:"295424",title:"Prof.",name:"Anuradha",surname:"Chakraborti",slug:"anuradha-chakraborti",fullName:"Anuradha Chakraborti"}]},{id:"68429",title:"Nemonoxacin (Taigexyn®): A New Non-Fluorinated Quinolone",slug:"nemonoxacin-taigexyn-sup-sup-a-new-non-fluorinated-quinolone",totalDownloads:305,totalCrossrefCites:0,authors:[{id:"284129",title:"Dr.",name:"Ming-Chu",surname:"Hsu",slug:"ming-chu-hsu",fullName:"Ming-Chu Hsu"},{id:"290925",title:"Prof.",name:"Ying-Yuan",surname:"Zhang",slug:"ying-yuan-zhang",fullName:"Ying-Yuan Zhang"},{id:"290926",title:"MSc.",name:"Li-Wen",surname:"Chang",slug:"li-wen-chang",fullName:"Li-Wen Chang"}]},{id:"66903",title:"Staphylococcus aureus in the Meat Supply Chain: Detection Methods, Antimicrobial Resistance, and Virulence Factors",slug:"-em-staphylococcus-aureus-em-in-the-meat-supply-chain-detection-methods-antimicrobial-resistance-and",totalDownloads:730,totalCrossrefCites:0,authors:[{id:"282838",title:"Ph.D.",name:"Valeria",surname:"Velasco",slug:"valeria-velasco",fullName:"Valeria Velasco"},{id:"289945",title:"Dr.",name:"Helia",surname:"Bello",slug:"helia-bello",fullName:"Helia Bello"},{id:"289946",title:"BSc.",name:"Mario",surname:"Quezada-Aguiluz",slug:"mario-quezada-aguiluz",fullName:"Mario Quezada-Aguiluz"}]},{id:"68398",title:"An Emerging Multidrug-Resistant Pathogen: Streptococcus pneumoniae",slug:"an-emerging-multidrug-resistant-pathogen-em-streptococcus-pneumoniae-em-",totalDownloads:335,totalCrossrefCites:1,authors:[{id:"291217",title:"Dr.",name:"Razique",surname:"Anwer",slug:"razique-anwer",fullName:"Razique Anwer"},{id:"291219",title:"Dr.",name:"Khalid",surname:"Alqumaizi",slug:"khalid-alqumaizi",fullName:"Khalid Alqumaizi"}]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"280415",firstName:"Josip",lastName:"Knapic",middleName:null,title:"Mr.",imageUrl:"https://mts.intechopen.com/storage/users/280415/images/8050_n.jpg",email:"josip@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copy-editing and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"8133",title:"Pathogenic Bacteria",subtitle:null,isOpenForSubmission:!1,hash:"b26e69f94525a38ead8ac88e3c68631a",slug:"pathogenic-bacteria",bookSignature:"Sahra Kırmusaoğlu and Sonia Bhonchal Bhardwaj",coverURL:"https://cdn.intechopen.com/books/images_new/8133.jpg",editedByType:"Edited by",editors:[{id:"179460",title:"Dr.",name:"Sahra",surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6148",title:"Bacterial Pathogenesis and Antibacterial Control",subtitle:null,isOpenForSubmission:!1,hash:"92128a5094670f6b0c9321640f60d3a3",slug:"bacterial-pathogenesis-and-antibacterial-control",bookSignature:"Sahra",coverURL:"https://cdn.intechopen.com/books/images_new/6148.jpg",editedByType:"Edited by",editors:[{id:"179460",title:"Dr.",name:"Sahra",surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8427",title:"Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods",subtitle:null,isOpenForSubmission:!1,hash:"0fdedc9bf6c23241235a0ae011c0304c",slug:"antimicrobials-antibiotic-resistance-antibiofilm-strategies-and-activity-methods",bookSignature:"Sahra Kırmusaoğlu",coverURL:"https://cdn.intechopen.com/books/images_new/8427.jpg",editedByType:"Edited by",editors:[{id:"179460",title:"Dr.",name:"Sahra",surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6601",title:"Disinfection",subtitle:null,isOpenForSubmission:!1,hash:"ea121cf9b26d006bc6d7c7f92195852d",slug:"disinfection",bookSignature:"Sahra Kırmusaoğlu",coverURL:"https://cdn.intechopen.com/books/images_new/6601.jpg",editedByType:"Edited by",editors:[{id:"179460",title:"Dr.",name:"Sahra",surname:"Kırmusaoğlu",slug:"sahra-kirmusaoglu",fullName:"Sahra Kırmusaoğlu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2796",title:"Lactic Acid Bacteria",subtitle:"R & D for Food, Health and Livestock Purposes",isOpenForSubmission:!1,hash:"8d625f084ccba1e96cc326406074fe3f",slug:"lactic-acid-bacteria-r-d-for-food-health-and-livestock-purposes",bookSignature:"Marcelino Kongo",coverURL:"https://cdn.intechopen.com/books/images_new/2796.jpg",editedByType:"Edited by",editors:[{id:"138356",title:"Dr.",name:"J. Marcelino",surname:"Kongo",slug:"j.-marcelino-kongo",fullName:"J. Marcelino Kongo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2129",title:"A Search for Antibacterial Agents",subtitle:null,isOpenForSubmission:!1,hash:"1567c6402f459b018a6aabfd620aa3f7",slug:"a-search-for-antibacterial-agents",bookSignature:"Varaprasad Bobbarala",coverURL:"https://cdn.intechopen.com/books/images_new/2129.jpg",editedByType:"Edited by",editors:[{id:"90574",title:"Dr.",name:"Varaprasad",surname:"Bobbarala",slug:"varaprasad-bobbarala",fullName:"Varaprasad Bobbarala"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5056",title:"Actinobacteria",subtitle:"Basics and Biotechnological Applications",isOpenForSubmission:!1,hash:"46638f9636540f83f06226bf0e0a1e43",slug:"actinobacteria-basics-and-biotechnological-applications",bookSignature:"Dharumadurai Dhanasekaran and Yi Jiang",coverURL:"https://cdn.intechopen.com/books/images_new/5056.jpg",editedByType:"Edited by",editors:[{id:"48914",title:"Dr.",name:"Dharumadurai",surname:"Dhanasekaran",slug:"dharumadurai-dhanasekaran",fullName:"Dharumadurai Dhanasekaran"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5867",title:"Antibacterial Agents",subtitle:null,isOpenForSubmission:!1,hash:"7834e622de76478416bdc3092c52cb15",slug:"antibacterial-agents",bookSignature:"Ranjith N. Kumavath",coverURL:"https://cdn.intechopen.com/books/images_new/5867.jpg",editedByType:"Edited by",editors:[{id:"163692",title:"Dr.",name:"Ranjith",surname:"Kumavath",slug:"ranjith-kumavath",fullName:"Ranjith Kumavath"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"554",title:"Bacterial Artificial Chromosomes",subtitle:null,isOpenForSubmission:!1,hash:"3092adcfb46acf538c9ef38530f92d8f",slug:"bacterial-artificial-chromosomes",bookSignature:"Pradeep Chatterjee",coverURL:"https://cdn.intechopen.com/books/images_new/554.jpg",editedByType:"Edited by",editors:[{id:"91537",title:"Dr.",name:"Pradeep",surname:"Chatterjee",slug:"pradeep-chatterjee",fullName:"Pradeep Chatterjee"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6764",title:"Cyanobacteria",subtitle:null,isOpenForSubmission:!1,hash:"87c7d8f86f7c1185aa4dd47c6492951a",slug:"cyanobacteria",bookSignature:"Archana Tiwari",coverURL:"https://cdn.intechopen.com/books/images_new/6764.jpg",editedByType:"Edited by",editors:[{id:"186791",title:"Dr.",name:"Archana",surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"39664",title:"Infections in Leukemia",doi:"10.5772/50193",slug:"infections-in-leukemia",body:'Despite significant advances in supportive care, infectious complications continue to be a significant cause of morbidity and mortality in leukemia patients. The implementation of empiric antibiotic therapy in febrile neutropenia led to dramatic reduction in mortality and was hailed as a turning point in cancer treatment [1]. Nonetheless, the development of more effective and dose intensive salvage chemotherapy regimens, incorporation of monoclonal antibodies, use of consolidation and maintenance strategies, and increased use of indwelling venous catheters have increased susceptibility to infections and changed the spectrum of infections in patients with leukemia [1]. Specifically, multidrug resistant organisms, as well as those previously considered innocuous have emerged. Even under the optimal circumstances i.e. timely diagnosis and implementation of appropriate therapy, infections in leukemia remain a therapeutic challenge. Furthermore, delayed recognition and/or poor implementation of the appropriate treatment strategy can lead to significant morbidity and mortality while potentially increasing the economic burden associated with the infections seen in this immunocompromised population. Therefore, it is imperative that clinicians caring for this vulnerable group of patients have a thorough understanding of the infectious complications associated with leukemia and leukemia directed therapy.
This chapter includes a discussion of
Basic concepts and definitions;
Pathogenesis of infections in acute and chronic leukemia;
Spectrum of infections, with a focus on new and emerging infections;
Risk of certain infections associated with specific chemotherapy medications;
Clinical evaluation of suspected infection;
Treatment strategies, including empiric therapy and management of documented infection;
Role of prophylactic and preventive measures, in patients with acute and chronic leukemia;
Economic impact and outcomes.
Fever in a neutropenic patient is usually defined as a single temperature >38.3ºC (101ºF), or a sustained temperature >38ºC (100.4ºF) for more than one hour [2].
Neutropenia is defined as an absolute neutrophil count (ANC) of less than 500cells/ microL whereas ANC less than 100 cells /microL is indicative of profound neutropenia [2].
Innate immunity refers to the body\'s natural resistance. It provides the first line of defense against a variety of pathogens. Innate immunity is not disease or pathogen specific and is composed of anatomic (skin and mucous membranes), physiologic (body temperature, gastric pH), and chemical (complement system) mediators, lysozyme and toll like receptors, phagocytic, and inflammatory aspects [3].
Adaptive immunity mediated by lymphocytes is a slower but highly specific response to antigen stimulation [3]. B and T lymphocytes receive whole or partially processed antigens from antigen presenting cells from lymphoid tissue (lymph nodes and the spleen). These cells multiply at the site of infection to evoke a highly targeted antigenic response. Cytotoxic T (CD8+) lymphocytes spearhead the body’s defense against intracellular pathogens. Helper T( CD4+) lymphocytes play a supportive role in providing necessary signals to CD8+ T lymphocytes that help not just in the primary response to infection, but also in the generation of memory CD8+ T cells and recruitment of CD8+ cells at the site of infection [4]. B lymphocytes secrete antibodies, process and present antigens and transform into a pool of memory B cells for future defense [4]. This capacity to retain immunologic memory is the distinguishing feature of adaptive immunity. Studies in murine models have demonstrated that NK cells, not just B and T lymphocytes possess the capacity to transform into memory cells [5]. Immunologists have customarily considered Natural killer (NK) cells as a part of the innate system due to their ability to respond rapidly albeit non- specifically to infection [5]. However unlike B and T lymphocytes that can generate responses to an unlimited range of antigen-specific receptors, NK cells can generate antigen specific responses limited to a population but not at an individual level. These cells are thought to represent a developmental transition between the innate and adaptive immune systems [5].
The acute leukemias are characterized by the rapid proliferation of immature progenitor cells and include acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Chronic leukemias typically run a more indolent course. This group includes chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). The accumulation and slow proliferation of mature appearing but functionally incompetent leukocytes is the common underlying pathology in chronic leukemias. The clinical presentations of infections are determined by a complex interplay between the pathogen and its virulence and the defense mechanisms of the host and the degree to which this is impaired.
Disease specific factors associated with host immune response
Studies in the early twentieth century led to a gradual shift in our understanding of the pathogenesis of infections. It became apparent that infections were not solely determined by the inherent virulence of the organism but also the susceptibility of the host [6].
In acute leukemia normal hematopoiesis is replaced by abnormal maturation and dysregulated proliferation of leukocytes [7]. Coupled with significant bone marrow infiltration, this leads to decreased production of normal granulocytes resulting in neutropenia and impaired granulocyte function. Additionally, the presence of a large number of immature myeloid cells can inhibit antigen specific T cell response [8] Therefore, newly diagnosed leukemia patients often present with concurrent infections [7]. Treatment with standard induction regimens results in prolonged neutropenia that can last weeks, rendering the host highly susceptible to bacterial and fungal infections [7]. Furthermore, polymorphonuclear leucocyte function may be adversely affected by several chemotherapeutic medications such as high dose glucocorticoids, vincristine, vinblastine, carmustine, cyclophosphamide and 6- mercaptopurine [9]. The risk of severe infections is not uniform among these patients and is related to the degree and duration of neutropenia [7] with the risk of developing more serious infections increasing with prolonged neutropenia [10] [11], the use of salvage chemotherapy, and previous antibiotic exposures [12]. In acute leukemia patients, the risk of infection does not fully abate after achieving remission as patients can have prolonged defects in humoral immunity [13]. This risk increases further with relapse of disease [14].
In addition, chemotherapy-induced mucosal disruption of the oropharynx and gastrointestinal tract enables normal commensals to access the bloodstream and cause invasive disease [15]. In the 1980s, the use of central lines became widespread and contributed to the increased incidence of blood stream and systemic infections with skin flora [15].
Patients with CLL have defects in both humoral and cellular immunity as a result of their underlying malignancy, as well as therapy-related immune suppression from chemotherapeutics such as alkylating agents, purine analogues and monoclonal antibodies [16]. Although these drugs have dramatically improved CLL outcomes, the predisposition to serious infections can result in significant morbidity - 80% of CLL patients will have a significant infection over the course of their disease, with up to 60% of people dying from infection [17].
B cell defects in patients with CLL can lead to hypogammaglobulinemia in the majority of patients (up to 70% within seven years of diagnosis) [18]. Deficiencies can be seen in all three classes of immunoglobulins -IgG, A and M and is worse with advanced disease stage [19, 20]. Severity and incidence of infections particularly respiratory infections correlated with low levels of serum IgG [19] as well as IgA [21,22]. Decreased levels of opsonizing antibodies typically result in infections due to encapsulated organisms such as Streptococcus pneumoniae, Haemophilus influenza, and Neisseria meningitides [17]. These patients also tend to respond poorly to vaccination [23]. Impaired function of NK cells (lack of azurophilic granules that are necessary for normal killing activity [24]), neutrophils (reduced chemotaxis and migration) and monocytes and macrophage system have also been noted. T cells show a number of defects including abnormalities in gene expression and CD30 response, decreased CD4 to CD8 ratio [25], impaired Th2 polarization, and reversible acquired CD40 ligand deficiency [26]) all of which prevent T cells from initiating or maintaining and completing an immune response[18]. Furthermore, patients can develop disease or therapy related neutropenia. These multiple immune defects predispose patients to bacterial, fungal, and viral infections.
Although the advent of improved diagnostics and more effective therapies have largely obviated the need for splenectomy across a number of hematologic malignancies, it may be performed for diagnostic reasons or in the setting of symptomatic splenomegaly, refractory autoimmune hemolytic anemia or thrombocytopenia [27,28]. The spleen is a large mass of lymphoid tissue pivotal in filtering blood borne pathogens. It is also an antibody producing organ [29] and plays a role in the activation of alternative complement pathway which may be abnormal in those with anatomic or functional asplenia [30]. Splenectomy therefore further predisposes this already at risk population serious infections including rapidly fatal infections with encapsulated organisms (see above), babesiosis, and capnocytophaga canimorsus [31-34].
HCL is an uncommon adult B-cell lymphoid leukemia that typically runs an indolent course and like CLL, many patients do not require immediate treatment [35]. Clinical features include pancytopenia, splenomegaly (which may be complicated by rupture or infarction), and absolute monocytopenia [35]. Infections remain a significant problem, presumably due to neutropenia and monocytopenia [36], and have been found to be prognostic. For example, survival at 4 years from diagnosis is markedly lower in individuals who have had infections as opposed to those who have not (49% versus 92%, p=0.0012)[36].
Age and malnutrition
Other factors that have been evaluated in the pathogenesis of infections in patients with leukemia include age and nutritional deficiencies. Fanci and colleagues compared the effect of age on the incidence of nosocomial infections in patients with acute leukemia older than 60 yrs compared to younger patients [37]. The authors concluded that the risk of infection was no different in the study groups despite the added decline in immune function with age. However these results needed to be evaluated with caution as they were likely confounded by the fact that elderly patients with relapsed/ refractory disease were generally treated with less aggressive treatment regimens [37] which inherently may be associated with less infectious risk.
Nutritional deficiencies may also adversely affect the ability of normal tissue to withstand toxicity from chemotherapy resulting in need for discontinuation or dose reduction of chemotherapy [38]; however, its impact on infections in leukemia is not well defined.
Key points
In acute leukemia there are quantitative and qualitative defects in leukocyte function.
The risk of infections in neutropenic fever is determined by the severity and duration of neutropenia.
Disruption of mucosal lining due to toxic effects of chemotherapeutic drugs and the use of central venous catheters contribute to the risk of infection due to commensal organisms.
In CLL both humoral and cellular immunity are impaired leading to a predilection to infection with encapsulated and intracellular organisms respectively.
Patients with HCL are also at increased risk for infections which may be associated with worse outcomes.
Febrile neutropenia
The most common bacterial pathogen in the 1960s in neutropenic patients was Staphylococcus aureus [10,39]. However, presumably due to the widespread use of methicillin, fatal staphylococcal infection rates dropped from 23.5% in 1954 to 3.1% in 1963 according to a ten year review of National Cancer Institute data [40]. This success was dampened in the late 1960s and early 1970s by the emergence of aerobic gram-negative bacilli such as Klebsiella pneumonia, enterobacter, E. coli, Pseudomonas and other enteric organisms such as enterococci and anerobes[39]. Cephalothin, a first-generation cephalosporin, led to improved outcomes with these infections. This period marked the emergence of Pseudomonas aeruginosa as a major pathogen associated with high mortality rates in this population [39]. Although polymyxin and gentamicin were available as monotherapies to treat Pseudomonas bacteremia, the use of the first anti-pseudomonal carboxy penicillin carbenicillin, in combination with gentamicin, significantly reduced mortality from 60% in the 1960s to 10-30% in the 1980s [39].
In the 1990s, given their oral route of administration, broad spectrum of activity including against gram negatives, good bioavailability, and general low toxicity, prophylactic fluoroquinolone use became widespread. In addition, emerging resistance patterns resulted in an increased reliance on third generation cephalosporins for prophylaxis, empiric therapy for neutropenic fever, or treatment of gram negative infections. These developments, along with the increased use of implantable venous catheters, shifted the spectrum of infections back towards gram positive organisms such as staphylococcus and streptococcus species [41]. Use of H2 antagonists and other antacids in conjunction with fluoroquinolones have also been implicated as a potential contributing factor to this shift [41,42].
Bloodstream infections (BSI) are commonly associated with mucositis, cellulitis, pneumonia, neutropenic enterocolitis, invasive fungal disease and central venous catheters [43,44]. The clinical presentations of BSI may vary from bacteremia to fulminant shock. In a survey of 49 hospitals between 1995 and 2001, the frequency of gram positive bloodstream infections increased from 62% in 1995 to 76% in 2001[45]. The source of BSI was not identified in 52% of cases in this study. One hospital based study reported the re-emergence of gram negative organisms in primary nosocomial BSI [46]. Interestingly, a seasonal increase in the incidence of gram negative BSI, particularly Acinetobacter, and to a lesser degree E.coli has recently been noted, stressing a need for greater vigilance during summer months [47]. The epidemiology of BSI is included in Table 1. Coagulase negative staphylococci, Staphylococcus aureus, Viridans streptococci, and gram negatives are the most likely pathogens. Although candida is well known as a cause of catheter related blood stream infection, atypical catheter related infections from mycobacteria, nocardia, and Tsukamurella have been reported [48-52].
It should be emphasized that gram-negative organisms continue to dominate the scene as the most frequent pathogens causing infections in febrile neutropenic patients. Apart from BSI, other sites of infection include the respiratory tract (pneumonia, sinus), skin and soft tissue (mucositis and cellulitis), gastrointestinal (diarrhea, typhlitis, perirectal abscess, and enterocolitis) and genitourinary tract (UTI,) in order of frequency [53-55]. Neutropenic enterocolitis, notorious for its morbidity and mortality may be further complicated by polymicrobial BSI due to aerobic gram negative bacilli and anerobes such as Clostridium septicum [56]. The gastrointestinal tract (including the oral cavity) is often the site of origin of polymicrobial BSI. Elting and colleagues delineated factors associated with the poor response to treatment in a large study of polymicrobial infections in cancer patients. These included persistent neutropenia (25%), pneumonia (19%), and bloodstream infection caused by multiple gram-negative organisms (49%) [57].
Clinical syndromes | Pathogens/ Risk factors |
Upper gastrointestinal -Gingivostomatitis and periodontal lesions | Streptococci, gram negatives, herpes simplex, candida and uncommon bacteria like stomatococcus and aerococcus |
Gastrointestinal infections- Typhlitis, neutropenic enterocolitis, perirectal abscess | Gram negatives and anerobes, C-diff. |
Lower respiratory tract infections-Pneumonia [64][65] | Gram negative bacilli, pneumococci, moulds, virus e.g CMV |
Blood stream infections [45,66]. | Coagulase negative staphylococcus (the most common isolate), S. aureus, E.coli and P.aeruginosa |
Polymicrobial infections [67] | Gram-positive, anaerobic, or fungal , often seen with concurrent presence of a gram-negative bacillus. |
Skin and soft tissue -cellulitis and folliculitis | Streptococci, staphylococci, anaerobes and gram negatives |
Sites of infection in neutropenic patients
Clostridium difficile associated diarrhea is common is patients with acute leukemia especially AML [58,59]. It accounts for approximately one third of episodes of diarrhea and is more common with older age, number and duration of antibiotics and prolonged neutropenia prior to onset of diarrhea [59]. Fluoroquinolone use has been implicated in the increased incidence of resistant Clostridium difficile (C-diff) infections [60]. Toxin negative Clostridium infections which have been described in up to 10% of patients, are particularly problematic, and require endoscopic studies for diagnosis [61]. C-Diff therapy consists of metronidazole or, in severe cases, oral vancomycin [62], which has become the initial agent of choice at some institutions [63] due to increasing emergence of metronidazole resistance. Fidaxomicin is a new macrocyclic antibiotic has been shown to have clinical cure rates similar to vancomycin but superior in terms of lower recurrence rates [62]. Table 1 summarizes the clinical syndromes, sites of infection and associated pathogens in neutropenic patients.
Resistant bacterial pathogens
Patients with leukemia are predisposed to infections and thus exposed to multiple antibiotics during the course of their therapy. The emergence of resistant organisms in this cohort of patients can be catastrophic.
Methicillin resistant Staphylococcus aureus (MRSA): accounts for 20-30% of nosocomial BSI and can lead to metastatic complications such as deep tissue and focal abscesses (e.g epidural, splenic), endocarditis and septic arthritis. MRSA is resistant to penicillin, cephalosporins and quinolones.
Vancomycin resistant staphylococci (VRSA): has become a growing concern no doubt due to the widespread use of vancomycin. Although linezolid and daptomycin can be used, these isolates may be less sensitive to these agents as well [68].
Vancomycin sensitive and vancomycin resistant enterococci (VRE): Risk factors include neutropenia, fluoroquinolone use, and previous treatment with vancomycin. E. faecium, which is often vancomycin resistant, has now surpassed E. faecealis as the predominant organism and is associated with a two-fold risk of higher mortality-in excess of 70% in the setting of neutropenia. In an attempt to decrease this risk, some centers have begun to isolate immunosuppressed VRE-colonized patients and employ barrier precautions (i.e. gowns, gloves); however, it is not yet clear if this approach impacts the outcomes of VRE infections. Linezolid and daptomycin are reasonable therapeutic options for the treatment of VRE infection. [41,69,70].
Multidrug resistant gram negative organisms have become especially problematic presumably due to the widespread use of antibiotics in this population. Extended spectrum beta-lactamase producing bacteria, such as Klebsiella and E coli, are resistant to fluoroquinolones, cephalosporins and penicillins [71]. The carbapenams are usually effective in treatment. However in cases of carbapenamase producing Klebsiella, colistin can be used. Multidrug resistant pseudomonas requires colistin or polymixin B therapy [72].
Fungal infections
Invasive fungal infections (IFI) have been implicated as a complication in leukemia since the 1940s [10] and continue to be a major cause of morbidity and mortality in leukemia patients. Autopsy studies identified IFI as a cause of persistent fever and subsequent demise in neutropenic patients unresponsive to broad spectrum antibiotic therapy [10]. The use of empiric antifungal therapy led to improved survival; however, it was often difficult to confirm a diagnosis of IFI. This in turn often led to overtreatment with antifungal medications and thereby significant treatment related costs and morbidity [73]. Table 2 outlines the spectrum of fungal infections in neutropenic seen in leukemia patients. Although candidiasis and aspergillosis continue to be the predominant pathogens, additional fungi have emerged (Table 2). IFI should be suspected in the setting of persistent fever despite broad spectrum antibiotics.
Fungal Pathogen | Clinical features |
Candida spp. [74] | Most common IFI infection. Severe immune suppression, broad spectrum antibiotics and central venous catheters are risk factors. Clinical presentation can range from BSI, gastrointestinal candidiasis and acute disseminated candidiasis. |
Trichosporon spp. [75][76] | Unusual fungal infection more often diagnosed per case reports in AML patients. It presents similar to candidemia and may also be associated with skin, kidney and lung findings if disseminated. |
Cryptococcus[76] | Rare in leukemia, likely due to widespread prophylaxis with fluconazole, but if seen, occurs most often in AML, CLL and CML. Underlying severe T cell depletion, diabetes mellitus and use of steroids are added risk factors. Lung and nervous system often affected. |
Aspergillus sp[77][78][74][79] | Lungs, sinus and CNS infections often seen. Risk factors include prolonged neutropenia especially AML and steroid use (non neutropenic patients). Lung infections can present as fever, cough, pleuritic chest pain and massive pulmonary hemorrhage. Nodular pneumonia and CT finding of a nodule with a halo sign are characteristic. Serum galactomannan (GM) assay used with variable success in screening and diagnosis. Bronchoalveolar lavage (BAL) galactomannan optical density "/> 3.0 had 100% positive predictive value and less than 0.5 had high negative predictive value. False positive GM may be seen with concomitant administration of piperacillin/tazobactam, severe gastrointestinal mucosal disruption, and pneumocystis (PJP). |
Zygomycetes [80-82] | Presents similar to aspergillus infections. Pathogenesis involves vascular invasion and tissue infarction manifesting as pulmonary, rhinocerebral and cutaneous infections. May progress rapidly; mortality in excess of 80% in disseminated disease. |
Scedosporium [76)][83] | Can cause skin or pulmonary involvement. Associated with high mortality. Surgical drainage of fluid collections in skin, joint or soft tissue and systemic treatment are the cornerstones of therapy. |
Endemic mycoses [84-88] | Reactivation of endemic fungal infections such as histoplasmosis, blastomycosis and coccidiomycosis can occur in the setting of immune suppression and can occur several years after leaving the region of original infection. Histoplasmosis may present in a disseminated fashion. |
Fungal infections in leukemia
Key points
In neutropenic patients gram negative organisms remain the most frequent pathogens at sites other than blood stream infections.
Gram positive organisms particularly oral commensals emerged as the leading cause of bloodstream infections in the 1980s.
A number of factors such as the increased use of antibiotic prophylaxis and indwelling venous catheters have altered the spectrum of infections in leukemia patients.
Clostridium Difficile infection has emerged as a major cause of morbidity in leukemia patients.
Persistent fever after 4-7 days of broad spectrum antibiotics may indicate occult IFI.
Non- neutropenic patients
Among non-neutropenic patients with leukemia, a number of bacterial, viral, fungal and other opportunistic infections have been described. With the introduction of newer immunosuppressive or more aggressive therapies such as purine analogues, multiagent combination chemotherapy, monoclonal antibodies and steroids, the increased frequency of more atypical infections. With the introduction of newer immunsosuppressive or more aggressive therapies more atypical infections, such as CMV, Pneumocystis jirovecci pneumonia (PJP), liseria meningitis, and IFI have been seen highlighting the need for deliberation when selecting the the appropriate treatment regimen. Individuals at greatest risk of infection include those who have active disease, have undergone multiple previous treatment regimens, and longer disease duration [18].
Among the infections in patients with both acute and chronic leukemia, listeriosis is notable for its predilection for the central nervous system [90, 91]. Listeria is a gram positive bacillus that gains entry into the blood stream via the gastrointestinal tract [90]. Listeriosis can present with bacteremia or with CNS involvement (meningitis [92], meningoencephalitis or cerebritis). Steroid therapy and nucleoside analogs such as fludarabine, which deplete T cells, are treatment associated risk factors [90]. Ampicillin is the drug of choice, although vancomycin, carbapenams, fluoroquinolones and linezolid have good in vitro activity. Among viral infections, herpes virus reactivation is relatively common, with localized Herpes zoster reported more often than [93] disseminated infections [94-96]. In addition, Epstein-Barr virus (EBV) reactivation is important and has been implicated in Richter’s transformation [97].
Tuberculosis is seen in CLL more frequently than in other hematological malignancies [98]. This is especially true for patients treated with fludarabine and the anti-CD52 monoclonal antibody alemtuzumab (as described in section C) [98]. Atypical mycobacterial [99] infection in chronic leukemia is linked to a high mortality especially if disseminated [99-101]. Clinical sites include skin [102,103], lung and multifocal osteomyelitis [104], but occasionally there may be no signs and symptoms other than fever. Bone marrow culture has a high diagnostic yield.
PJP can rapidly progress from fever and dyspnea to acute respiratory failure in a few hours [16]. Parasitic infections such as toxoplasmosis and strongyloidiasis are rare in leukemic patients but have been described. For example, cerebral toxoplasmosis has been linked to patients with fludarabine refractory CLL with profound CD4 lymphopenia [105] and is associated with high mortality.
Key points
Non-neutropenic patients with leukemia are susceptible to a host of bacterial, viral, IFI and other opportunistic infections.
Patients with CLL and HCL who have been treated with newer immunosuppressive therapies remain profoundly lymphopenic several months after cessation of therapy and at risk for various opportunistic infections.
Factors associated with increased risk of infection include duration of disease, T cell depletion, active disease and individuals who have undergone multiple prior therapies.
Other emerging pathogens
Unless the treating physician is aware of the pathogenic potential of bacteria widely believed to be harmless in the immunocompetent host, positive culture results may be dismissed as insignificant or as a contaminant.
Fusarium is a mold that can cause rapidly fatal infections. Skin involvement is common and blood cultures are often positive. High dose liposomal amphotericin is the treatment of choice [106-110].
Corynebacterium (e.g Corynebacterium\n\t\t\t\t\t\t\tpseudodiphtheriticum, Corynebacterium\n\t\t\t\t\t\t\tjeikeium) Corynebacterium is a gram positive bacillus that may present clinically as catheter related infections, pneumonia, endocarditis, urinary infections, keratitis and sepsis [111]. Immunoglobulin deficiency in CLL is a predisposing factor [112]. Mortality in the neutropenic host can be as high as 34% [111]. Corynebacterium\n\t\t\t\t\t\t\tjeikeium is resistant to multiple antibiotics and vancomycin is the recommended antibiotic of choice [113].
Stenotrophomonas\n\t\t\t\t\t\t\tmaltophilia is a gram negative bacillus that normally resides in the oral mucosa. Patients with prolonged neutropenia and T cell defects may present with life threatening syndromes of hemorrhagic pneumonia and ecthyma gangrenosum. Trimethoprim-sulfamethoxazole and fluoroquinolone-based multidrug combination regimens are used as first line treatment [114-117].
Bacillus\n\t\t\t\t\t\t\tcereus: A gram-positive rod that is typically associated with foodborne illness in the immunocompetent host. Patients can present with pneumonia, necrotizing gastritis, septic shock, multiorgan failure, disseminated intravascular coagulation, brain abscess, critical illness polyneuropathy and myopathy. Leukemia patients, particularly ALL patients, are more vulnerable. Risk factors that predict poor outcomes include severe neutropenia, presence of central venous catheters and CNS symptoms [118-122].
Lactobacillus is a gram positive bacillus that may cause infection in the neutropenic patient. It presents usually as sepsis or pneumonia. Importantly, vancomycin has poor activity against Lactobacillus, and treatment with penicillin or related compounds is recommended instead [123].
Alkylating agents and Anthracyclines
Anthracyclines (idarubicin, daunorubicin, and doxorubicin) are unique among chemotherapeutic drugs in that they induce apoptosis of hematopoietic cell lines [124] in the G0-G1 phases of the cell cycle. They can deplete the peripheral T-cell pool and cause neutropenia secondary to myelosuppresion.[124] which can result in bacterial infections and IFI. However the incidence of gram negative infections and ≥ grade3 /4 infections (i.e. requiring IV antibiotics) may be reduced by the use of pegylated liposomal doxorubicin possibly due to reduced overall myelotoxicity [125].
Alkylating agents (e.g chlorambucil, cyclophosphamide, melphalan, bendamustine etc) cause DNA damage and prevent DNA repair activity both in normal and leukemic cells [126]. Pyogenic infections due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Klebsiella and E. coli account for the vast majority of infections in patients treated with alkylating agents [17]. These frequently involve the respiratory tract; however, infections of the urinary tract, skin and soft tissue can also occur. BSI are more likely to be seen in neutropenic patients. Candidiasis and aspergillosis occur in patients with prolonged neutropenia or who are treated concomitantly with high-dose steroids, prolonged antibiotic therapy, combination chemotherapy. Nocardia, listeria, mycobacteria and PJP can occur but are uncommon in CLL patients treated with alkylating agents alone [17].
Purine and Pyrimidine analogues
Purine nucleosides cladribine, fludarabine and pentostatin have been extensively used in CLL, HCL and other indolent B cell lymphoproliferative disorders. The risk of infections with these agents is related to both quantitative and qualitative T cell defects. Their use can result in prolonged suppression of all T cells especially CD4 cells, which can last up to 11-40 months after completion of treatment [127] [17]. Consequently, as noted previously, the spectrum of infections broadens to include organisms such as Listeria, Nocardia, and mycobacteria. Disseminated candidiasis and aspergillosis are well recognized offenders. Concurrent treatment with steroids increases the likelihood of pneumocystis infections [93]. Viral infections are common, especially varicella zoster virus (VZV) infection, which may be complicated by a high incidence of post-herpetic neuralgia. Reactivation of hepatitis B, adenovirus and cytomegalovirus (CMV) infections have been described [17]. Cladribine has been used in CLL and HCL and can also cause prolonged suppression of CD4 cells which may recover at a a median of 40 months after therapy with CD8 cells returning to normal at 3 months [127]. Purine nucleosides are stem cell toxic [128] and thus, may induce severe bone marrow suppression. The incidence of severe neutropenia has been reported as varying from 16-42% [129,130] and may persist for many months after completion of therapy. However, documented infections-where a pathogen is identified- are less common at 7-13%[129,130]. Clofarabine is a second-generation nucleoside analog approved for the treatment of childhood ALL. It has been studied alone or in combination with cytarabine or idarubcin in adult patients with relapsed and/or refractory acute leukemia [131,132]. The risk of myelosuppression and neutropenic fever is very high. In one study, Grade 4 neutropenia (ANC < 500) occurred in all patients and 38% developed a bacterial infection [12].
Of the pyrimidine analogs, cytarabine (cytosine arabinoside, Ara-C) is widely used in the treatment of both AML and ALL. Mayer and colleagues presented the results of using low (100 mg/m2), intermediate (400 mg/m2) and high dose cytosine arabinoside (3 gm/m2) for post remission chemotherapy in adult patients with AML. Myelosuppression resulted in ≥ Grade 3 neutropenic fever -significant to require hospital admission- in 71% [133] of patients in the high dose arm. Treatment-related deaths during remission, attributable to infections occurred in 1, 6 and 5% percent of the patients assigned to the low, intermediate and high dose groups respectively [133].
Corticosteroids
Corticosteroids are synthetic analogs of hormones produced in the adrenal cortex and are frequently used in the management of leukemia patients, particularly those with lymphoid malignancies. Despite their widespread benefits, the risk of infections is well known. Steroids impair T cell and neutrophil function, may camouflage classic signs and symptoms of inflammation, and are an independent risk factor for serious opportunistic infections in patients receiving other immunosuppressive therapy such as induction chemotherapy, alkylating agents and nucleoside analogues [17] [89].
A wide spectrum of bacterial, viral (CMV, HSV, VZV), fungal, tubercular and opportunistic infections have been reported in patients treated with chronic steroids [134,135].
Infections associated with corticosteroids are dependent on the route of administration (parenteral worse risk than oral route), dose, and duration of therapy -daily dose greater than 10 mg per day or a cumulative dose of more than 700 mg- as evidenced by data from 71 clinical trials [135]. Unfortunately this analysis excluded trials in which patients were already on antiviral, antibacterial or antifungal prophylaxis, preventative practices common in this group of patients.
Monoclonal antibodies
Monoclonal antibodies have gained popularity for the treatment of various hematological malignancies. They potentially allow for more narrowly directed therapy for these diseases by targeting specific antigens expressed on the cell surface of malignant cells. However, normal hematopoetic cells express the target as well, resulting in off target effects. While a number immune conjugates, which incorporate antibody directed delivery of various toxins, have been developed, the majority of commercially available monoclonal antibodies rely on complement mediated and antibody mediated cytotoxicity against the malignant cells [136) which can disrupt adaptive immunity.
Rituximab is directed against CD20, which is a cell surface antigen expressed on B cells. It has limited use in CLL as monotherapy in part due to the limited expression of CD20 on malignant B cells in CLL [137]. However, it has been shown to significantly improve outcomes when added to other agents [138). Neutropenia that can be seen including late onset neutropenia occuring several weeks to months after treatment, is typically self-limited with no clinically significant risk of infections, and appears to be linked to B cell recovery [139]. Rituximab has been associated with reactivation of hepatitis B infection, which may be severe enough to require urgent liver transplantation [140], as well as progressive multifocal leukoencephalopathy (PML), which is due to reactivation of JC virus [141,142].
Ofatumumab is a novel fully humanized anti-CD20 monoclonal antibody recently approved for the treatment of CLL refractory to alemtuzumab and fludarabine [148]. In the pivotal study, Grade 5 (fatal) infections were seen in 10% [149] of patients with pneumonia being the most frequent cause of infection. In a similar study 8-12% of patients developed grade 3 or 4 infections while receiving ofatumumab treatment [150] although the degree of additional immunosuppression mediated directly by ofatumumab is debatable as these patients were already severely immunosuppressed at the initation of therapy. Similar to rituximab, ofatumumab can cause neutropenia, however, the risk of grade 3 or 4 neutropenia in this heavily pre-treated populations was significantly higher (42% grade 3, 18% grade 4) [151].
Alemtuzumab: Alemtuzumab is a humanized monoclonal antibody directed against CD52, a cell surface glycopeptide expressed on virtually all human lymphocytes, monocytes and macrophages, a small subset of granulocytes, but not on erythrocytes, platelets or bone marrow stem cells [137]. Alemtuzumab is used in the treatment of CLL and T cell prolymphocytic leukemia. Given the near ubiquitous expression of CD52 on immune cells, treatment results in the loss of circulating T cells, leading to defective cell mediated immunity and neutropenia in approximately 1/3 of patients. As a result, CMV reactivation occurs in 15 to 25% of patients and is the most commonly observed opportunistic infection [137,143-145]. Other infections include herpes simplex, varicella zoster, PJP, candidiasis, cryptococcosis, toxoplasmosis and mold infections(aspergillosis and mucormycosis) [17] It is recommended that all patients receiving alemtuzumab receive antiviral prophylaxis (acyclovir, valacyclovir or famciclovir). Although valganciclovir is effective in preventing CMV reactivation [146], it can suppress bone marrow function and current guidelines recommend weekly screening for CMV viremia using PCR, and pre- emptive treatment with ganciclovir or foscarnet when patients are symptomatic or show increase in viremia [144]. In a Cancer and Leukemia Group (CALGB) study by Lin et al [147] alemtuzumab was administered to patients who received induction therapy with fludarabine and rituximab. Improved complete response was noted, but event free survival did not improve due to serious infections (including listeria meningitis, CMV reactivation and PCP pneumonia) which occurred up to 7 months after completion of therapy [147].
Tyrosine Kinase inhibitors
Tyrosine kinase inhibitors (TKI) disrupt T-cell receptor mediated T-cell proliferation, activation and selective inhibition of memory CTL responses without interfering with primary T or B cell responses. Imatinib is the first agent in this class and has significantly improved the outcomes of CML patients [152]. In a study of 250 CML patients treated with imatinib the most frequently seen infections were pneumonia, herpes zoster reactivation and urinary tract infections. The incidence of opportunistic infections was low [153].
Dasatinib is a multikinase inhibitor used for CML and ALL. It acts both as an antineoplastic and immunosuppressive agent at doses 140 mg or above. Grade 3 or 4 infections are more problematic in the accelerated phase compared to the chronic phase of the disease (89% versus 45%) [154] which is likely related to the underlying disease process.
Nilotinib
Nilotinib is an orally bioavailable TKI with increased selectivity for bcr-abl relative to other targets such as Src family or c-kit kinases. This probably accounts for the high efficacy of nilotinib without severe myelosuppression [155]. Although all tyrosine kinase inhibitors cause myelosuppression, nilotinib is associated with more garden variety types of infections. In a phase II trial involving 280 patients with CML in chronic phase, grade 3/4 neutropenia (ANC < 1000) was noted in 29% of patients with a median duration of 15 days and need for dose interruptions or modifications in 10% of patients [155].
Key points
Atypical infections are common in patients with CLL and HCL treated with monoclonal antibodies and purine nucleosides.
Alemtuzumab is particularly immunosuppressive and its use requires close monitoring for CMV reactivation as well as prophylaxis for PJP and fungal infections.
Concurrent use of steroids significantly increases the risk of infections.
Risk of severe infections may persist for months after cessation of therapy.
The risk of infections in patients with CML receiving TKIs is relatively low.
Neutropenic fever is a medical emergency and thus requires prompt evaluation and initiation of empiric therapy. While a variety of noninfectious causes including transfusion of blood products, medications, and the underlying malignancy itself, may cause fever, the presence of fever should always be presumed to be due to an underlying infection until proven otherwise. Initial evaluation of the neutropenic patient should include a complete history, with special attention given to identifying prior chemotherapies, previous infectious complications, and recent or current prophylactic antimicrobial therapies. A thorough physical examination, blood and bodily fluid cultures -based on clinical suspicion-, and appropriate radiographic imaging are integral to the evaluation of these patients. Clinicians should be aware that in the neutropenic host, signs and symptoms of infection may be blunted by a decreased inflammatory response and therefore, a high index of clinical suspicion is essential for expeditious diagnosis and treatment. For example, only 8% of neutropenic patients with pneumonia produce sputum compared to 84% in non neutropenic patients [64].
In order to better stratify which patients require more intensive management, scoring systems and treatment algorithms have been devised. For example, the Multinational Association for Supportive Care in Cancer (MASCC) scoring system is a well validated tool for risk stratification of febrile neutropenic patients based on the burden of illness (mild, moderate or severe), absence of hypotension, absence of chronic obstructive lung disease, absence of dehydration, age less than 60 years, outpatient status at the time of onset of fever and solid tumor or lymphoma with no previous fungal infection [156,157]. A cumulative score of 20 or more is predictive of a less than 5% chance of developing serious medical complications. This is a valuable tool to identify low risk patients who may be treated as an outpatient [158]. However, it is more common practice to observe the patient in the hospital for at least 24 hours on empiric IV antibiotics to confirm low risk status [159].
Key. points
Patients with neutropenic fever should undergo a rapid and comprehensive evaluation.
MASCC scoring can be used as a general guide to help risk stratify patients and identify those who would benefit from outpatient treatment noting that most leukemia patients are high risk and warrant a period of hospitalization.
The four basic approaches to infections in leukemia patients include prophylactic (prevention of infection in high risk individuals by appropriate medications), empiric (initiating treatment on symptomatic individuals before positive cultures), pre-emptive (initiating treatment on the basis of positive or rising titers at the onset of clinical or radiological signs[160]) and traditional (treatment based on positive cultures).
During the 1950s it was not common practice to initiate antibacterial therapy before a specific pathogen was identified [10]. Not surprisingly, this fundamental principle was associated with high mortality rate among neutropenic leukemia patients. Early randomized trials failed to demonstrate improved outcomes with the use of empiric antibiotics in the management of febrile neutropenia [161]. However, shortly thereafter, subsequent studies in leukemia patients showed a significant benefit for patients treated with empiric antibiotic therapy prior to bacteriological data becoming available [162,163]. This established the paradigm of empiric antibiotic use which is still used to guide the initial approach to managing neutropenic leukemia patients. In the setting of neutropenic fever, treatment of the most likely focus should be initiated and include coverage for the most virulent and prevalent pathogens. In the absence of an obvious focus, broad spectrum empiric therapy covering gram positives and gram negatives should be initiated and be guided by institutional protocols based on local resistance patterns pending results of initial tests. Initial combination therapy should take into consideration any recent antibiotic prophylaxis, prior infections including with resistant organisms, presenting signs and symptoms, exam findings, severity of infection, organ function, and co-morbidities.
The three basic antibiotic regimens include: 1) monotherapy with an antipseudomonal beta-lactam such as cefepime, 2) a beta lactam plus an aminoglycoside or a fluoroquinolone, and 3) a glycopeptide in addition to beta lactam monotherapy. Due to the concern for emergence of resistance, vancomycin is not routinely used in the empiric treatment of neutropenic fever unless any of the following criteria are met: positive blood cultures with smears showing gram positive cocci, critically ill patients, presence of skin or soft tissue infection, suspicion of catheter related infection, or known colonization or prior infection with MRSA [2].
There are several options for the treatment of MRSA infection. Vancomycin has been used traditionally for this indication. Vancomycin dosing should be adjusted based on trough levels, with a goal trough of 15-20 mcg/mL.[164] Toxicities associated with high trough levels include renal injury, ototoxicity, and myelosuppresison. Vancomycin should not be used to treat MRSA infection if the MIC of the MRSA is ≥ 2 µg/ml due to a high rate of treatment failure [164]. Daptomycin has become the second-line agent of choice for MRSA infections. Daptomycin can induce eosinophilic pneumonia [165] and has been associated with rhabdomyolysis (package insert). Linezolid has the advantage of good bioavailability after oral administration, but is bacteriostatic against MRSA and therefore, should be used with caution in life-threatening MRSA infections. Myelosuppression, serotonin syndrome when administered concurrently with serotonin uptake inhibitors (SSRI)), and rhabdomyolysis are notable linezolid related toxicities [166,167]. Ceftaroline is a new cephalosporin that has activity against MRSA and is approved for use in skin and soft tissue infections [168]. Doxycycline, TMP/SMX, and clindamycin all possess activity against most MRSA isolates but are traditionally reserved for the treatment of non-life threatening infections such as uncomplicated skin and soft tissue infections.
Even with the initiation of the appropriate empiric antibiotic, it may take days for fevers to abate in neutropenic patients; however, if fevers persist without an obvious focus or culture result after 4-7days of antibacterial therapy, persistent fever atypical organisms and IFI must be considered. In this case, empiric antifungal therapy may be initiated while further diagnostic tests are done. Prompt removal of catheters is essential if suspected to be the source of infection. Due to the widespread use of fluconazole and posaconazole as antifungal prophylaxis, the possibility of azole resistance should be borne in mind. In the treatment of candidemia, IDSA guidelines recommend fluconazole for the less critically ill who have not been exposed to this drug or echinocandins, such as micafungin or caspofungin [169]. Voriconazole or liposomal amphotericin may be used as first line in more critically ill individuals. Voriconazole has emerged as a safe and more efficacious alternative to liposomal amphotericin for the empiric treatment of fungal infections in febrile neutropenia [170] and as the primary therapy of invasive aspergillosis [171] based on two landmark randomized trials. The 2008 IDSA guidelines recommend voriconazole as first line therapy for invasive aspergillosis [2,74]. This drug has high bioavailability in both oral and intravenous forms. For patients who fail voriconazole or therapy is limited by toxicity such as hallucinations, hepatotoxicity, or skin rash, conventional amphotericin B or liposomal preparation can be used [74]. Both forms of amphotericin have similar success rates but the latter has less toxicity allowing for the use of higher doses. Infusional toxicity (fever, chills, and hypotension), potassium and magnesium wasting and frequent renal toxicity are complications of amphotericin.
The three echinocandins in clinical use are caspofungin, micafungin and anidulafungin. This class of medications inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall [172]. All three drugs are fungistatic against Aspergillus spp although the minimal effective concentration for micafungin and anidulafungin are 2- 10 fold lower than caspofungin [172]. Caspofungin has been approved for use in refractory aspergillosis or invasive disease where other treatment options cannot be tolerated. It has also been used as a single agent in pulmonary aspergillosis in patients with hematological malignancies [173]. Micafungin has a clinical efficacy that is comparable to caspofungin [174]. Unlike, the other echinocandins anidulafungin is unique in that it undergoes elimination by breakdown in the bile rather than via hepatic metabolism [172] and like micafungin has the added advantage of not requiring dose reduction in moderate liver disease [172].
Surgical debridement followed by antifungal treatment for zygomycosis (mucormycosis) with lipid formulations of amphotericin B is the standard of care [74]. Posaconazole is recommended as salvage therapy but not as first line [175]. Voriconazole is the drug of choice in the treatment of scedosporium [176]. The optimal duration of therapy in these infections has not been determined by clinical trials and is largely determined by the treating physician.
Observational studies have indicated increased mortality with delay in starting antifungal therapy [177,178]. The dilemma in initiating prompt antifungal therapy is complicated by the fact that fewer than 5% patients who receive empiric therapy go on to develop or demonstrate evidence of IFI in the first 48 hours [179]. Therefore, with the increasing availability of newer diagnostic techniques in IFI, there is an interest in active surveillance with non-culture based methods and initiation of treatment before the onset of signs and symptoms. This pre-emptive therapy, although being practiced by clinicians, is still considered experimental [180] and the NCCN (National Comprehensive Cancer Network) does not currently recommend pre- emptive therapy due to lack of sufficient evidence to support routine use [181]. However, a number of leukemia centers have adopted prophylactic and empiric treatment strategies which incorporate anti-fungal therapy. Although combination therapy for invasive aspergillosis has shown therapeutic promise in a number of small studies [182,183], this approach has not been validated in large prospective randomized studies and is not currently recommended.
In PJP infections, CXR can show bilateral alveolar infiltrates although a normal CXR does not exclude the diagnosis. Gold standard for diagnosis is direct immunofluorescence to detect the organism although recently measurement of 1-3-beta-d- glucan is being studied with interest. So far it has not shown reliable prognostic value and can be elevated in several mycoses making it a very non- specific test [184,185]. Trimethoprim/ sulfamethoxazole is the first line of therapy and is the standard prophylactic agent. Other options include pentamidine, trimerexate atovaquone and clindamycin. A high index of suspicion should be maintained especially in patients who have received ongoing steroids or T-cell depleting therapies.
Key points:
Empiric treatment with broad spectrum coverage in the absence of an obvious focus should follow institutional guidelines according to local resistance patterns.
Delay in instituting empiric antibiotic and antifungal therapy is associated with worse outcomes.
One should consider IFI if fever persists > 4-7 days in the setting of appropriate broad spectrum antibiotic therapy and negative cultures.
If a source of infection is identified, the therapy should be appropriately tailored/ adjusted.
Preemptive therapy involves active surveillance to detect viral and fungal infections based on rising titers and institution of treatment with onset of symptoms
A number of antifungal therapies are available for the treatment of fungal infections in leukemia patients and should be selected based on the suspected pathogen, severity of illness, and co-morbidities.
PJP infection should be suspected in patients with unexplained hypoxia, even in the setting of a normal chest xray, especially in patients who have received T-cell depleting therapy.
Due to the high mortality and costs associated with infections, there is a great interest in preventing them. Various approaches have been adopted and this is an area of active research.
Antibiotics: IDSA recommends prophylactic FQ for high risk patients defined as patients with expected durations of prolonged and profound neutropenia( ANC ≤ 100 cells/mm3 for > 7 days)[2] Among the FQ, ciprofloxacin has maximum activity against Pseudomonas whereas levofloxacin has the added advantage of activity against some gram positives and once a day dosing at the expense of less anti- pseudomonal coverage[186]. The main concern with the use of FQ has been the emergence of resistant bacteria. However, surprisingly, in the setting of febrile neutropenia, this increase in resistant organisms has not translated into increased infectious mortality. [187].[60]
Antiviral: NCCN recommends acyclovir or valacyclovir for patients with acute leukemia or T cell depleting therapy for HSV seropositive individuals throughout the neutropenic phase and a minimum of 2 months after alemtuzumab therapy or until the circulating CD4 count is more than 0.2 ×109/L [181]. Patients who are inactive carriers of hepatitis B virus should receive lamivudine 100 mg daily for 3 months following cessation of chemotherapy [181]. Preemptive influenza chemoprophylaxis with oseltamivir, amantadine or rimantidine is recommended after known exposure to a confirmed case during an established outbreak [181].
Antifungals: Outside of bone marrow transplant there is very little evidence to support the routine use of antifungal prophylaxis. IDSA recommends prophylaxis against candida with fluconazole, itraconazole, voriconazole, posaconazole, micafungin, or caspofungin for patients undergoing intensive remission induction or salvage chemotherapy in acute leukemia [2]. In this group IDSA also recommends use posaconazole for prophylaxis against aspergillosis [2]. In patients with AML or myelodysplastic syndrome undergoing chemotherapy posaconazole prevented IFI compared to fluconazole or itraconazole and was associated with improved overall survival [188]. NCCN recommends antifungal prophylaxis only in leukemia patients receiving mucotoxic regimens including cytarabine and anthracycline [181] PJP prophylaxis is recommended for patients receiving alemtuzumab [181] however, many centers have adapted widespread use of PJP prophylaxis in patients receiving any T-cell depleting therapy.
Colony stimulating factors (CSF): The main benefit of CSF is in hastening time to recovery of neutrophil function and number of hospital days but these have not been shown to affect mortality [189]. ASCO guidelines recommend use of CSF in patients at increased risk of complications from prolonged neutropenia such as age > 65 yr, poor performance status, malnutrition, advanced cancer, bone marrow infiltration, active or open wounds, and/or extensive prior treatment [190]. Secondary prophylaxis is recommended in individuals who experienced complications due to neutropenia during a prior cycle [190]. Given the potential concern for promotion of myeloid stimulation in active AML, myeloid growth factors are typically not given during primary induction therapy. However, they are typically utilized in patients after consolidation therapy.
Intravenous immunoglobulin (IVIG): IVIG is not routinely advised in patients with CLL due to lack of known benefit in preventing life threatening infections. However, it should be considered in those with recurrent sinopulmonary infections or in those with underlying refractory CLL. In a multicenter double-blind study, 84 CLL patients at high risk for infections (history of hypogammaglobulinemia, infections, or both) were randomized to receive IV immunoglobulin G (IVIG) (400 mg/kg) every 3 weeks or placebo. Although moderate bacterial infections were reduced by 50%, there was no subsequent reduction in mortality [191]. Another study found that the number of infection related admissions was reduced with IVIG administration [192]. However in a cost effective analysis it was determined that IVIG therapy resulted in a 0.8 day per patient per quality adjusted life year at a cost of $6 million per year gained implying a prohibitive cost for minimal benefit [193]. This was mainly due to the loss of quality of life due to the need to receive IV infusion every 3 weeks. The authors estimated that even if immune globulin were to be given free of cost, treatment would result in a net savings of only $814 because of lower infection rates and, thus, lower medical costs. At a cost of $50 per treatment, the marginal cost of treatment equals that of no treatment [193].
Active immunization: Annual influenza vaccination is recommended for all cancer patients lifelong [2]. Immunization responses in CLL patients are variable but suboptimal. One study found that 73% of stage zero CLL patients had decreased levels of at least one immunoglobulin. Vaccination is most successful if used earlier in the disease, when immunoglobulin levels are better preserved, and if protein or conjugated vaccines are used [194]. Response to hemophilus and tetanus vaccines may be enhanced by the use of adjuvant ranitidine but it has no beneficial effect on the response to vaccination with unconjugated polysaccharide antigens [195]. Given the immunosuppressive effects of leukemia directed treatment, it is recommended that vaccines not be performed in the peri-chemotherapy period. Live vaccines including polio (oral), typhoid (oral), yellow fever, measles, mumps, rubella, BCG and Herpes zoster should not be administered to patients with CLL [18].
Vaccine based strategies to prevent IFI are hampered by the fact that the population that will most benefit from this approach is able to mount the least immune response.. Torosantucci et al have developed a fungal vaccine consisting of laminarin that was protective against candidiasis and aspergillosis [196]. Currently, developing vaccines for this immunosuppressed patient population remains an active area of research [197].
Key. points
Prophylactic antibiotics, antivirals and antifungals should be given to patients at highest risk for these infections.
The role of IVIG in CLL is controversial and not routinely recommended due to lack of cost effectiveness although moderate reduction in infections have been noted and its use should be considered in patients with hypogammaglobulinemia and recurrent sinopulmonary infections.
Patients with CLL should be vaccinated earlier in their disease to reap maximum benefit due to decline in antibody response with disease duration.
Live virus vaccines should be avoided in immunosuppressed patients.
Growth factors shorten the duration of neutropenia but do not impact mortality.
Infections increase the costs of treatment in patients with leukemia and can drastically influence the economic burden of the disease [198]. There are no recent direct studies that have addressed the economic burden related to infections in patients with leukemia. However, in 2000, aggregate US hospital costs were 2.1 billion dollars with AML being the most costly leukemia followed by ALL, CML and CLL [198]. In patients with CLL, infections have been shown to contribute to higher total cost of care [198]. Patients with leukemia who are critically ill have worse outcomes than non- cancer patients. Relapsed/ refractory status of disease and high Sequential Organ Failure Assessment (SOFA) score (a simple and objective score that allows for calculation of both the number and the severity of organ dysfunction in six organ systems -respiratory, coagulation, liver, cardiovascular, renal, and neurologic) [199] have been found to be predictive of high mortality [200]. Among ICU survivors 1 year mortality for acute leukemia patients is lower than patients with other malignancies [201]. In a study by Thakkar et al evaluating predictors of outcome for patients with acute leukemia admitted to the ICU, respiratory distress was the most frequently observed reason for ICU admission or transfer with the majority requiring ventilator support [202]. The two, six, and twelvemonth overall survival was 24 (27%), 16 (18%), and 14 (16%), respectively. Higher APACHE II score (a severity of disease classification system that helps prognostically risk stratify acutely ill patients) [203], use of vasopressors, undergoing bone marrow transplantation preparative regimen, and adverse cytogenetics were predictors of worse outcomes whereas a new diagnosis of leukemia, type of leukemia and age were not significant. [202].
A study by Schapira in 1993 evaluated the economic cost of survival in patients with hematologic malignancies. Factors noted to be significant for survival included: the nadir platelet count and albumin level prior to and during the ICU stay, the BUN, creatinine, and the need for mechanical ventilation. Seventy-eight percent of patients survived less than five months and spent less than two and a half months at home after discharge. Fifty percent of patients expired during their ICU stay. The cost per year of life gained for the entire group of patients was $189,339 per.admission [204]. However, this study did not differentiate between relapsed/refractory or de novo disease. Documented infection was noted in 54.7% of individuals who expired in the hospital. Among patients who were discharged from the hospital, documented infections were noted in 29.3% of patients who survived for less than 6 months but in only 16% of patients who survived for more than 6 months. Taken together, these studies highlight the impact of infections in leukemia patients, especially those with relapsed/refractory disease, with a direct correlation to hospital mortality and post discharge survival [204].
Careful patient selection improves outcomes without the burden of futile economic costs. It has been recommended that patients with good performance status, where life prolonging treatment options are available- especially patients with new or recent diagnosis of leukemia, should be given the benefit of intensive care support, while patients with poor prognosis who may benefit from a palliative care approach should not. This is often a difficult choice for the treating provider. A middle of the road approach might be to initiate ICU care unless declined by the patient with a goal to regularly reassess the patients wishes and/or condition [205] and proceed to comfort care if continued aggressive therapies are deemed to be of minimal benefit.
Key points
Intensive care costs for treatment of patients with leukemia are significant
Careful selection of patients improves outcomes without adding significantly to economic costs.
Patients with refractory or relapsed leukemia and poor performance status are unlikely to benefit from ICU stay
Identifying low risk patients with neutropenia using MASCC scoring can help minimize the costs of treatment of neutropenic fever.
With rapid advances in diagnostic techniques and availability of newer chemotherapeutic and antibiotic medications in the armamentarium against leukemia, the spectrum of infections continues to change. Clinicians face evolving clinical, diagnostic and ethical challenges to select the most cost effective and evidence based care. The cornerstone of therapy should however be an individualized and patient oriented approach in order to achieve the best outcomes.
Oxidoreductases, which includes oxidase, oxygenase, peroxidase, dehydrogenase, and others, are enzymes that catalyze redox reaction in living organisms and in the laboratory [1]. Interestingly, oxidoreductases catalyze reaction involving oxygen insertion, hydride transfer, proton extraction, and other essential steps. The substrate that is oxidized is considered as hydrogen or electron donor, whereas the substrate that is reduced during reaction as hydrogen/electrons acceptor. Most commonly, oxidoreductase enzymes use NAD, FAD, or NADP as a cofactor [2]. Organisms use this group of enzymes for synthesis of biomolecules, degradation and removal of molecules, metabolism of exogenous molecules like drugs, and so on [3, 4, 5]. Their biochemical property such as efficiency, specificity, good biodegradability, and being studied well make it fit well for industrial purposes. As a result, oxidoreductases are being utilized in nutrition, food processing, medicine, and other chemical synthesis. In the near future, oxidoreductase may be utilized as the best biocatalyst in pharmaceutical, food processing, and other industries [6, 7].
Enzymes like oxidoreductase play great and significant function in the field of disease diagnosis, prognosis, and treatment [8]. By analyzing the activities of enzymes and changes of certain substances in the body fluids, a number of disease conditions can be diagnosed [9, 10]. The determination of the activity of the oxidoreductases is helpful in understanding the metabolic activity of different organs [8, 11]. For example, the activity of oxidoreductase enzymes in Krebs cycle is significantly increased during skin infection [12].
There are different disease conditions resulting from deficiency (quantitative and qualitative) and excess of oxidoreductase, which may contribute to the metabolic abnormalities and decreased normal performance of life [13, 14]. For example, relative decreases in the activities of NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase are highly associated with the developments of peripheral arterial disease. Another best example is mutation of p450 oxidoreductase (POR) gene, which leads to insufficiency of P450 enzymes characterized by defective steroidogenesis. Similarly, deficiency of mitochondrial acetaldehyde dehydrogenase disturbs normal metabolism of alcohol and leads to accumulation of acetaldehyde [8, 15, 16]. These conditions in turn affect the normal development and reproduction.
Oxidoreductases are a family of enzymes that catalyze redox reactions. Oxidoreductases catalyze the transfer of electrons from oxidant to reductant [4]. Generally, oxidoreductases catalyze reactions which are similar to A– + B → A + B– where A is the oxidant and B is the reductant [17]. Oxidoreductases can be oxidases where a molecular oxygen acts as an acceptor of hydrogen or electrons and dehydrogenases which are enzymes that oxidize a substrate by transferring hydrogen to an acceptor that is either NAD+/NADP+ or a flavin enzyme. Other classes are oxidoreductases enzymes, peroxidases which are localized in peroxisomes and catalyze the reduction of hydrogen peroxide. Hydroxylases are involved in the addition of hydroxyl groups to their substrates, and oxygenases are key in the incorporation of oxygen from molecular oxygen into organic substrates. And reductase enzymes are involved in the catalysis of reduction reaction [2, 3, 18]. In general, oxidoreductase enzymes play an important role in both aerobic and anaerobic metabolism. They are involved in glycolysis, TCA cycle, oxidative phosphorylation, fatty acid, and amino acid metabolism [5, 19, 20].
In glycolysis, the enzyme glyceraldehydes-3-phosphate dehydrogenase catalyzes the reduction of NAD + to NADH. In order to maintain the redox state of the cell, this NADH must be re-oxidized to NAD+, which occurs in the oxidative phosphorylation pathway [21].
A high number of NADH molecules are produced in the TCA cycle. The product of glycolysis, pyruvate, enters the TCA cycle in the form of acetyl-CoA. Except leucine and lysine, all twenty of the amino acids can be degraded to TCA cycle intermediates. And most of the fatty acids are oxidized into acetyl coA through beta oxidation that enter TCA cycle [19, 22].
The precursor for the TCA cycle comes from lipids and carbohydrates, both of which produce the molecule acetyl-CoA. This acetyl-CoA enters the eight-step sequence of reactions that comprise the Krebs cycle, all of which occur inside mitochondria of eukaryotic cells. TCA or Krebs cycle produces NADH and FADH, and the reactions are catalyzed by classes of oxidoreductase enzymes [23].
Living cells use electron transport chain to transfer electrons stepwise from substrates (NADH & FADH2) to a molecular oxygen. The proton gradient which is generated through electron transport chain runs downhill to drive the synthesis of ATP. Electron transport chain and oxidative phosphorylation take place in the matrix of mitochondria, and there are oxidoreductase enzymes impregnated in the inner mitochondrial membrane, which catalyze these reactions and are engaged in energy production. NADH:quinone oxidoreductase, also called NADH dehydrogenase (complex I), is responsible for the transfer of electrons from NADH to quinones, coupled with proton translocation across the membrane. Succinate:quinone oxidoreductase, or succinate dehydrogenase (complex II), is an enzyme of the Krebs cycle, which oxidizes succinate and reduces quinones, in the absence of proton translocation. Quilon:cytochrome c oxidoreductase (complex III), which transfers electrons from quinols to cytochrome c and cytochrome c:oxygen oxidoreductase, an aa3-type enzyme (complex IV), which receives these electrons and transfers it to oxygen are both oxidoreductase enzymes involved in electron transport chain and oxidative phosphorylation [19, 24, 25] (Figure 1).
Oxidoreductase enzymes involved in electron transport chain and oxidative phosphorylation [18].
Liver is the principal organ for drug metabolism. The body uses different strategies to metabolize drugs like oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. The main goal of drug metabolism is to make the drug more hydrophilic and excrete easily. Enzymes involved in drug metabolism are found in many tissues and organs but are more concentrated in the liver. Rates of drug metabolism may vary among individuals. Some individuals metabolize a drug so rapidly; in others, metabolism may be so slow and have different effects. Genetic factors, coexisting disorders (particularly chronic liver disorders and advanced heart failure), and drug interactions are responsible factors for variation of rate of drug metabolism among individuals [26].
Generally, drug metabolism can be in three phases. In phase I drug metabolism, oxidoreductase enzymes such as cytochrome P450 oxidases add polar or reactive groups into drugs (xenobiotics). In phase I reaction, drugs are introduced into new or modified functional group through oxidation, reduction, and hydrolysis. In Phase II reactions, modified compounds are in conjugation with an endogenous substance, e.g., glucuronic acid, sulfate, and glycine. Phase II reactions are synthetic, and compounds become more polar and thus, more readily excreted by the kidneys (in urine) and the liver (in bile) than those formed in nonsynthetic reactions. At the end, in phase III reaction, the conjugated drugs (xenobiotics) may be further processed, before being recognized by efflux transporters and pumped out of cells. The metabolism of drug often converts hydrophobic compounds into hydrophilic products that are more readily excreted [27].
In normal cases, human body wants to remove or detoxify any compounds that cannot be metabolized otherwise utilized to serve the needs of the body. This removal process is carried out mainly by the liver. The liver has classes of oxidoreductase enzymes that are extremely effective at detoxification and removal of drugs from the body [5, 18].
Oxidation and metabolism of a high number of drugs and endogenous molecules are catalyzed by a class of oxidoreductase enzymes called cytochrome P450 monooxygenases. Even though they are distributed throughout the body, cytochrome P450 enzymes are primarily concentrated in liver cells. The CYP2D6 isozymes play a great role in metabolizing certain opioids, neuroleptics, antidepressants, and cardiac medications. Currently it is going to be understood that difference in the genes for CYP450 enzymes play to inter-individual differences in the serum concentrations of drug metabolites, resulting in interpatient variability in drug efficacy and safety [28].
Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) are a family of microsomal NADPH-dependent oxidoreductase, responsible for oxygenation of nucleophilic nitrogen, sulfur, phosphorus, other drugs, and endogenous molecules. Different variants of mammalian FMOs play a significant role in the oxygenation of nucleophilic xenobiotics. FMO utilizes NADPH as a cofactor and contains one FAD as a prosthetic group. FMOs have a broad substrate specificity and their activity is maximal at or above pH 8.4. FMO is a highly abundant enzyme in the liver endoplasmic reticulum and participates in drug metabolism (activation and detoxification) [29].
Before FMOs bind to a substrate, they activate molecular oxygen. First, flavin adenine dinucleotide (FAD), the prosthetic group of FMO, is reduced by NADPH to form FADH, then oxygen is added into the FAD, and hydro-peroxide FADH-4α-OOH is produced. And then, one oxygen atom is transferred to the substrate [30, 31].
Alcohol dehydrogenase (ADH) and mitochondrial aldehyde dehydrogenase (ALDH) are another family of oxidoreductase responsible for metabolizing ethanol. These enzymes are highly expressed in the liver but at lower levels in many tissues and play a great role in detoxification and easy removal of alcohols. Liver is the main organ for ethanol metabolism. Oxidation of ethanol with these enzymes can become a major energy source especially in the liver, and it can interfere metabolism of other nutrients [32].
The first step in ethanol metabolism is its oxidation to acetaldehyde, and this reaction is catalyzed by enzymes called alcohol dehydrogenases (ADHs). The second reaction in ethanol metabolism is oxidation of acetaldehyde into acetate catalyzed by aldehyde dehydrogenase (ALDH) enzymes. There are different ADH and ALDH enzymes encoded by different genes occurring in several alleles and enzymes that have different alcohol metabolizing capacity; thereby, they influence individuals’ alcoholism risk. These are either through rapid oxidation of ethanol to acetaldehyde where there is more active ADH or slower oxidation of acetaldehyde into acetate where there are less active ALDH enzymes. Excess accumulation of acetaldehyde is toxic, which results in different adverse reactions and produces nausea, skin rash, rapid heartbeat, etc. Most commonly, single-nucleotide polymorphisms (SNPs) are responsible for ADH and ALDH gene variants, and these may occur on both coding and non-coding regions of the gene [33, 34].
Monoamine oxidase is a very important oxidoreductase enzyme mainly responsible for degradation of amine neurotransmitters like norepinephrine, epinephrine, serotonin, and dopamine. Oxidation of different endogenous and exogenous biogenic amines may produce other active or inactive metabolites. Monoamine oxidase (MAO) is found in two isozyme forms: monoamine oxidase A (MAO-A) preferentially deaminates serotonin, norepinephrine, epinephrine, and dietary vasopressors such as tyramine, and MAO-B preferentially deaminates dopamine and phenethylamine. They are integral flavoproteins components of outer mitochondrial membranes in neurons and glia cell. The two isozymes of MAO differ based on substrate specificity and sensitivity to different inhibitors [35].
Monoamine oxidase enzymes catalyze the primary catabolic pathway for 5-HT oxidative deamination. Serotonin is converted into 5-hydroxy-indoleacetaldehyde, and this product is further oxidized by a NAD-dependent aldehyde dehydrogenase to form 5-hydroxyindoleacetic acid (5-HIAA). Immunohistochemical techniques and in situ hybridization histochemistry techniques are used to study the neuroanatomical localization and biochemical nature of the two forms of MAO [36].
Different antidepressant drugs like phenelzine and tranylcypromine inhibit the activity of monoamine oxidase. These are a result of MAO metabolizes biogenic amines such as 5-HT, DA, and NE. In addition, different dopaminergic neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are metabolized by MAO [37].
Another essential class of oxidoreductase enzyme is NADPH-cytochrome P450 reductase (CPR). It is a membrane-bound protein localized in the ER membrane. PR involves in the detoxification and activation of a number of xenobiotics. CPR uses FAD and FMN as cofactors, and it transfers the hydride ion of NADPH to FAD, and then FAD transfers electrons to FMN and other oxidases. Finally, it reduces the P450 enzyme heme center to activate molecular oxygen. Thus, electrons transfer from NADPH to the P450 heme center by CPR, which is central for P450-catalyzed metabolism. Flow of electron can be expressed as follows:
Human cytochrome P450 reductase is encoded by the POR gene. It is a 78-kDa multi domain diflavin reductase that binds both FMN and FAD and is attached to the cytoplasmic side of the endoplasmic reticulum via a transmembrane segment at its N-terminus [5, 15, 38].
Several industries such as pharmaceutical, foods, biofuel production, natural gas conversion, and others have used enzyme catalysis at commercial scale [39]. Classes of oxidoreductase enzymes are becoming a target by a number of industries. The family of oxidoreductase like heme-containing peroxidases and peroxygenases, flavin-containing oxidases and dehydrogenases, and different copper-containing oxidoreductases is involved in synthesis and degradation of interested products by the above industries and they are biocatalysts of interest for establishing a bio-based economy. Oxidoreductase enzymes have the highest potential in the production of polymer building blocks, sustainable chemicals, and materials from plant biomass within lignocellulose biorefineries [6, 7, 40].
Enzymes are biological catalysts and have great specificity, efficiency, and selectivity in the reaction they catalyze [39]. Oxidoreductase enzymes have different redox-active centers for doing their functions. These unique features of oxidoreductase enzymes make it valuable targets of pharmaceutical and chemical industries. Advancement in recombinant DNA technology, protein engineering, and bioinformatics is a critical event in the application of enzymes in different industries. A number of dug synthesis processes require the involvement of oxidoreductase enzymes [6].
An oxidoreductase is involved in the synthesis of 3,4-dihydroxylphenyl alanine (DOPA), and 3,4-dihydroxylphenyl alanine is a drug used for treatment of Parkinson’s disease [41]. Similarly, a class of oxidoreductase called monoamine oxidase (MAO) catalyzes enantiomeric desymmetrization of bicyclic proline intermediate, which is an important precursor in the synthesis of boceprevir. Boceprevir is a NS3 protease inhibitor that is used for the treatment of chronic hepatitis C infections. Using MAO in this reaction reduces time and waste product generation and is economically cost-competitive and profitable [42]. Its coenzyme specificity makes oxidoreductase an effective biocatalyst in protein engineering [43]. In vitro different oxidoreductase enzymes are involved in regeneration of coenzymes, pyridine nucleotides, NAD(H) and NADP(H). Alcohol dehydrogenase and format dehydrogenase are frequently used enzymes for recycling of coenzymes, and the intermediate products are useful in the synthesis of pharmaceutical drugs such as mevinic acid [44, 45].
Enzymes are biological catalysts and have a number of applications in agricultural fields. Using enzymes has great efficacy and efficiency over chemical catalysts with respect to their productivity, time, cost, quality, and quantity products. There are different classes of oxidoreductase enzymes nowadays involved in fertilizer production, dairy processing, and other food processing in agricultural sector, and their cost-effectiveness and quality product were confirmed by a number of researches [3].
Manipulation of gene cod for different oxidoreductase in plants can also change the characters of plants in a way that it increases productivity and resists adverse effects of herbicide and environmental changes. For example, modification of DNA for glyphosate oxidoreductase (GOX) enzyme that catalyzes the oxidative cleavage of the C▬N bond on the carboxyl side of glyphosate, resulting in the formation of aminomethylphosphonic acid (AMPA) and glyoxylate thereby augmented expression of GOX plants, results in glyphosate herbicide side effect tolerance [46, 47]. Some families of oxidoreductase like xanthine dehydrogenase in plants are used to metabolize reactive oxygen species associated with plant-pathogen and protect plants from stress-induced oxidative damage. Upregulation of xanthine dehydrogenase expression in plants is helpful to increase productivity [48, 49].
Classes of oxidoreductase are also involved in dairy processing. Glucose oxidase produced by fungal species acts as preservatives in dairy products and other foods. The intermediate and end product of glucose oxidase have antimicrobial effect [50]. Isozyme of xanthine oxidoreductase in bovine milk, which catalyzes reduction of oxygen to generate reactive metabolite is used as an anti-microbial agent in the neonatal gastrointestinal tract [51]. Similarly, peroxidases which are a family of oxidoreductase found in higher plants catalyze the oxidation of many compounds including phenolics, in the presence of hydrogen peroxide responsible in browning or darkening of noodles and pasta and associated with a grain quality defect [52]. Protochlorophyllide oxidoreductase (POR), which exists in two isozymes POR A and POR B, plays a vital role in plant chlorophyll synthesis, and manipulation on these genes can induce plant development [53]. In general, there are a number of oxidoreductase enzymes found in plants, and their normal activity is crucial for qualitative and quantitative productivity of crops, and these were confirmed by a number of active researches. Different interventions are also going on at gene level to control the expression of oxidoreductase enzymes in plant as needed [3].
Oxidoreductase enzymes are involved in a number of valuable biochemical reactions in the living organism, and their qualitative and quantitative normality is essential. For example, one important class of oxidoreductase is xanthine oxidoreductase (XOR) that catalyzes oxidative hydroxylation of hypoxanthine to xanthine then to uric acid and over activity XOR leads to hyperuricemia and concomitant production of reactive oxygen species. In turn, hyperuricemia is confirmed as an independent risk factor for a number of clinical conditions such as gout, cardiovascular disease, hypertension, and others. Different urate-lowering drugs or XOR inhibitors are nowadays implemented to prevent and manage hyperuricemia disorder [9].
Another important class of oxidoreductase enzyme is cytochrome P450 oxidoreductase (POR) that is essential for multiple metabolic processes. Cytochrome P450 enzymes are involved in metabolism of steroid hormones, drugs, and xenobiotics. Nowadays, more than 200 different mutations and polymorphisms in POR gene have been identified and cause a complex set of disorders. Deficiency of cytochrome P450 oxidoreductase affects normal production of hormone; specifically, it affects steroid hormones, which are needed for normal development and reproduction. This is highly linked with the reproductive system, skeletal system, and other functions. Signs and symptoms can be seen from birth to adult age with different severities. Individuals with moderate cytochrome P450 oxidoreductase deficiency may have ambiguous external genitalia and have a high chance of infertility but a normal skeletal structure [5, 16, 18].
Aldehyde dehydrogenase 2 (ALDH2) deficiency known as Asian glow or alcohol flushing syndrome is a common genetic health problem that interferes with alcohol metabolism, and ALDH2 is a classical family of oxidoreductase enzymes. It was confirmed that ALDH2 deficiency results in the accumulation acetaldehyde, which is a toxic metabolite of alcohol metabolism and responsible for a number of health challenges like esophageal, head, and neck cancer. A number of researches conclude that acetaldehyde is a group 1 carcinogenic metabolite [33, 54]. Similarly, monoamine oxidase deficiency, which is a family oxidoreductase enzyme, affects the normal metabolism of serotonin and catecholamines. It is a rare X-linked disorder characterized by mild intellectual disability, and behavioral challenges appear at earlier age. Monoamine oxidase-A deficiency that occurs almost exclusively in males has episodes of skin flushing, excessive sweating, headaches, and diarrhea. Monoamine oxidase-A deficiency can be diagnosed by finding an elevated urinary concentration of the monoamine oxidase-A substrates in combination with reduced amounts of the monoamine oxidase products [36, 55].
Mitochondria generate huge amounts of energy (ATP) to eukaryotic cells through oxidation of fats and sugars; and fatty acid β-oxidation and oxidative phosphorylation are two metabolic pathways that are central to this process. Qualitative and quantitative normality of oxidoreductase enzymes involved in oxidative phosphorylation and fatty acid oxidations are essential to get sufficient energy (ATP) form metabolism. Deficiency of a complex I (NADH-CoQ oxidoreductase) is common, and a well-characterized mitochondrial problem causes reduced ATP production [56]. Complex I (NADH-CoQ oxidoreductase) is responsible for recycling of NADH to NAD+, and in turn, this is essential to sustain Krebs cycle and glycolysis. Mutations in both nuclear and mitochondrial DNA for Complex I gene are responsible for mitochondrial disease. Individuals with mitochondrial diseases suffer from an energy insufficiency characterized by myopathies, neuropathy, delayed development, cardiomyopathy, lactic acidosis, and others. Furthermore, since mitochondria are a hub of metabolism, mitochondrial dysfunctions are highly associated with metabolic diseases like hypertension, obesity, diabetes, neurodegenerative diseases, and even aging. Deficiency of complex I leads to elevation of NADH levels in the mitochondria that inhibit pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. This condition completely inhibits Krebs cycle, and it is measured by CO2 evolution from [14C] labeled precursors. Similarly, complex II (succinate:ubiquinone oxidoreductase) deficiency affects both fatty acid oxidation and electron transport chain, and it induces retinopathies and encephalopathies [57, 58].
Deficiency of the pyruvate dehydrogenase complex (PDHC), another class of oxidoreductase enzymes, causes similar clinical and biochemical alteration in energy production with complex I (NADH-CoQ oxidoreductase) [59]. Both TCA cycle and respiratory chain can be affected by succinate dehydrogenase deficiency. Deficiency of oxidoreductase enzymes involved in Krebs cycle affects all carbohydrate, protein, fat, and nucleic acid metabolism as it is a common pathway for metabolism of the above macromolecules [60].
Oxidoreductase enzymes are also involved in bile acid synthesis. Classes of oxidoreductase enzymes called 3beta-hydroxy-Delta (5)-C (27)-steroid oxidoreductase catalyze an early step of bile acids synthesis from cholesterol and are encoded by HSD3B7 gene on chromosome 16p11.2-12. Mutations of HSD3B7 gene affect bile acids synthesis, cause development of progressive liver disease characterized by cholestatic jaundice, malabsorption of lipids, and lipid-soluble vitamins from the gastrointestinal tract, and finally progress to cirrhosis and liver failure [61].
One important biomolecule that acts as a precursor for other molecules and a component of cell membrane is cholesterol. Mammalian cells can get cholesterol from de novo biosynthesis or uptake of exogenously derived cholesterol associated with plasma low-density lipoprotein (LDL). 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is a class of oxidoreductase, catalyzes the rate-limiting steps of de novo cholesterol biosynthetic pathway and target for manipulation pharmacologically. Under or over activity of HMG-CoA reductase can disturb cholesterol homeostasis and lead to either hypercholesterolemia or hypocholesterolemia. And disturbed cholesterol level associated with number serious clinical problem like atherosclerosis [62, 63].
The authors declare that they have no competing interests.
Mezgeu Legesse Habte drafted the paper and write the literature review.
Etsegenet Assefa assisted in guidance, critical assessment and peer review of the writing. Both authors have given their final approval of this version to be published. Both authors read and approved the final manuscript.
Availability of data and material: All necessary data and materials related to the article are included in the article.
Funding: This review article is not funded by any person or organization (not funded).
As this section deals with legal issues pertaining to the rights of individual Authors and IntechOpen, for the avoidance of doubt, each category of publication is dealt with separately. Consequently, much of the information, for example definition of terms used, is repeated to ensure that there can be no misunderstanding of the policies that apply to each category.
",metaTitle:"Copyright Policy",metaDescription:"Copyright is the term used to describe the rights related to the publication and distribution of original works. Most importantly from a publisher's perspective, copyright governs how authors, publishers and the general public can use, publish and distribute publications.",metaKeywords:null,canonicalURL:"/page/copyright-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"Copyright is the term used to describe the rights related to the publication and distribution of original Works. Most importantly from a publisher's perspective, copyright governs how Authors, publishers and the general public can use, publish, and distribute publications.
\\n\\nIntechOpen only publishes manuscripts for which it has publishing rights. This is governed by a publication agreement between the Author and IntechOpen. This agreement is accepted by the Author when the manuscript is submitted and deals with both the rights of the publisher and Author, as well as any obligations concerning a particular manuscript. However, in accepting this agreement, Authors continue to retain significant rights to use and share their publications.
\\n\\nHOW COPYRIGHT WORKS WITH OPEN ACCESS LICENSES?
\\n\\nAgreement samples are listed here for the convenience of prospective Authors:
\\n\\n\\n\\nDEFINITIONS
\\n\\nThe following definitions apply in this Copyright Policy:
\\n\\nAuthor - in order to be identified as an Author, three criteria must be met: (i) Substantial contribution to the conception or design of the Work, or the acquisition, analysis, or interpretation of data for the Work; (ii) Participation in drafting or revising the Work; (iii) Approval of the final version of the Work to be published.
\\n\\nWork - a Chapter, including Conference Papers, and any and all text, graphics, images and/or other materials forming part of or accompanying the Chapter/Conference Paper.
\\n\\nMonograph/Compacts - a full manuscript usually written by a single Author, including any and all text, graphics, images and/or other materials.
\\n\\nCompilation - a collection of Works distributed in a Book that IntechOpen has selected, and for which the coordination of the preparation, arrangement and publication has been the responsibility of IntechOpen. Any Work included is accepted in its entirety in unmodified form and is published with one or more other contributions, each constituting a separate and independent Work, but which together are assembled into a collective whole.
\\n\\nIntechOpen - Registered publisher with office at 5 Princes Gate Court, London, SW7 2QJ - UNITED KINGDOM
\\n\\nIntechOpen platform - IntechOpen website www.intechopen.com whose main purpose is to host Monographs in the format of Book Chapters, Long Form Monographs, Compacts, Conference Proceedings and Videos.
\\n\\nVideo Lecture – an audiovisual recording of a lecture or a speech given by a Lecturer, recorded, edited, owned and published by IntechOpen.
\\n\\nTERMS
\\n\\nAll Works published on the IntechOpen platform and in print are licensed under a Creative Commons Attribution 3.0 Unported License, a license which allows for the broadest possible reuse of published material.
\\n\\nCopyright on the individual Works belongs to the specific Author, subject to an agreement with IntechOpen. The Creative Common license is granted to all others to:
\\n\\nAnd for any purpose, provided the following conditions are met:
\\n\\nAll Works are published under the CC BY 3.0 license. However, please note that book Chapters may fall under a different CC license, depending on their publication date as indicated in the table below:
\\n\\n\\n\\n
LICENSE | \\n\\t\\t\\tUSED FROM - | \\n\\t\\t\\tUP TO - | \\n\\t\\t
\\n\\t\\t\\t Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0) \\n\\t\\t\\t | \\n\\t\\t\\t\\n\\t\\t\\t 1 July 2005 (2005-07-01) \\n\\t\\t\\t | \\n\\t\\t\\t\\n\\t\\t\\t 3 October 2011 (2011-10-03) \\n\\t\\t\\t | \\n\\t\\t
Creative Commons Attribution 3.0 Unported (CC BY 3.0) | \\n\\t\\t\\t\\n\\t\\t\\t 5 October 2011 (2011-10-05) \\n\\t\\t\\t | \\n\\t\\t\\tCurrently | \\n\\t\\t
The CC BY 3.0 license permits Works to be freely shared in any medium or format, as well as the reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as the source Work is cited and its Authors are acknowledged in the following manner:
\\n\\nContent reuse:
\\n\\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\\n\\nContent adaptation & reuse:
\\n\\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\\n\\nReposting & sharing:
\\n\\nOriginally published in {full citation}. Available from: {DOI}
\\n\\nRepublishing – More about Attribution Policy can be found here.
\\n\\nThe same principles apply to Works published under the CC BY-NC-SA 3.0 license, with the caveats that (1) the content may not be used for commercial purposes, and (2) derivative works building on this content must be distributed under the same license. The restrictions contained in these license terms may, however, be waived by the copyright holder(s). Users wishing to circumvent any of the license terms are required to obtain explicit permission to do so from the copyright holder(s).
\\n\\nDISCLAIMER: Neither the CC BY 3.0 license, nor any other license IntechOpen currently uses or has used before, applies to figures and tables reproduced from other works, as they may be subject to different terms of reuse. In such cases, if the copyright holder is not noted in the source of a figure or table, it is the responsibility of the User to investigate and determine the exact copyright status of any information utilised. Users requiring assistance in that regard are welcome to send an inquiry to permissions@intechopen.com.
\\n\\nAll rights to Books and all other compilations published on the IntechOpen platform and in print are reserved by IntechOpen.
\\n\\nThe copyright to Books and other compilations is subject to separate copyright from those that exist in the included Works.
\\n\\nAll Long Form Monographs/Compacts are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license granted to all others.
\\n\\nCopyright to the individual Works (Chapters) belongs to their specific Authors, subject to an agreement with IntechOpen and the Creative Common license granted to all others to:
\\n\\nUnder the following terms:
\\n\\nThere must be an Attribution, giving appropriate credit, provision of a link to the license, and indication if any changes were made.
\\n\\nNonCommercial - The use of the material for commercial purposes is prohibited. Commercial rights are reserved to IntechOpen or its licensees.
\\n\\nNo additional restrictions that apply legal terms or technological measures that restrict others from doing anything the license permits are allowed.
\\n\\nThe CC BY-NC 4.0 license permits Works to be freely shared in any medium or format, as well as reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as it is not used for commercial purposes. The source Work must be cited and its Authors acknowledged in the following manner:
\\n\\nContent reuse:
\\n\\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\\n\\nContent adaptation & reuse:
\\n\\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\\n\\nReposting & sharing:
\\n\\nOriginally published in {full citation}. Available from: {DOI}
\\n\\nAll Book cover design elements, as well as Video image graphics are subject to copyright by IntechOpen.
\\n\\nEvery reproduction of a front cover image must be accompanied by an appropriate Copyright Notice displayed adjacent to the image. The exact Copyright Notice depends on who the Author of a particular cover image is. Users wishing to reproduce cover images should contact permissions@intechopen.com.
\\n\\nAll Video Lectures under IntechOpen's production are subject to copyright and are property of IntechOpen, unless defined otherwise, and are licensed under the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This grants all others the right to:
\\n\\nShare — copy and redistribute the material in any medium or format
\\n\\nUnder the following terms:
\\n\\nUsers wishing to repost and share the Video Lectures are welcome to do so as long as they acknowledge the source in the following manner:
\\n\\n© {year} IntechOpen. Published under CC BY-NC-ND 4.0 license. Available from: {DOI}
\\n\\nUsers wishing to reuse, modify, or adapt the Video Lectures in a way not permitted by the license are welcome to contact us at permissions@intechopen.com to discuss waiving particular license terms.
\\n\\nAll software used on the IntechOpen platform, any used during the publishing process, and the copyright in the code constituting such software, is the property of IntechOpen or its software suppliers. As such, it may not be downloaded or copied without permission.
\\n\\nUnless otherwise indicated, all IntechOpen websites are the property of IntechOpen.
\\n\\nAll content included on IntechOpen Websites not forming part of contributed materials (such as text, images, logos, graphics, design elements, videos, sounds, pictures, trademarks, etc.), are subject to copyright and are property of, or licensed to, IntechOpen. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance of the content on this site is strictly prohibited.
\\n\\nPolicy last updated: 2016-06-08
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Copyright is the term used to describe the rights related to the publication and distribution of original Works. Most importantly from a publisher's perspective, copyright governs how Authors, publishers and the general public can use, publish, and distribute publications.
\n\nIntechOpen only publishes manuscripts for which it has publishing rights. This is governed by a publication agreement between the Author and IntechOpen. This agreement is accepted by the Author when the manuscript is submitted and deals with both the rights of the publisher and Author, as well as any obligations concerning a particular manuscript. However, in accepting this agreement, Authors continue to retain significant rights to use and share their publications.
\n\nHOW COPYRIGHT WORKS WITH OPEN ACCESS LICENSES?
\n\nAgreement samples are listed here for the convenience of prospective Authors:
\n\n\n\nDEFINITIONS
\n\nThe following definitions apply in this Copyright Policy:
\n\nAuthor - in order to be identified as an Author, three criteria must be met: (i) Substantial contribution to the conception or design of the Work, or the acquisition, analysis, or interpretation of data for the Work; (ii) Participation in drafting or revising the Work; (iii) Approval of the final version of the Work to be published.
\n\nWork - a Chapter, including Conference Papers, and any and all text, graphics, images and/or other materials forming part of or accompanying the Chapter/Conference Paper.
\n\nMonograph/Compacts - a full manuscript usually written by a single Author, including any and all text, graphics, images and/or other materials.
\n\nCompilation - a collection of Works distributed in a Book that IntechOpen has selected, and for which the coordination of the preparation, arrangement and publication has been the responsibility of IntechOpen. Any Work included is accepted in its entirety in unmodified form and is published with one or more other contributions, each constituting a separate and independent Work, but which together are assembled into a collective whole.
\n\nIntechOpen - Registered publisher with office at 5 Princes Gate Court, London, SW7 2QJ - UNITED KINGDOM
\n\nIntechOpen platform - IntechOpen website www.intechopen.com whose main purpose is to host Monographs in the format of Book Chapters, Long Form Monographs, Compacts, Conference Proceedings and Videos.
\n\nVideo Lecture – an audiovisual recording of a lecture or a speech given by a Lecturer, recorded, edited, owned and published by IntechOpen.
\n\nTERMS
\n\nAll Works published on the IntechOpen platform and in print are licensed under a Creative Commons Attribution 3.0 Unported License, a license which allows for the broadest possible reuse of published material.
\n\nCopyright on the individual Works belongs to the specific Author, subject to an agreement with IntechOpen. The Creative Common license is granted to all others to:
\n\nAnd for any purpose, provided the following conditions are met:
\n\nAll Works are published under the CC BY 3.0 license. However, please note that book Chapters may fall under a different CC license, depending on their publication date as indicated in the table below:
\n\n\n\n
LICENSE | \n\t\t\tUSED FROM - | \n\t\t\tUP TO - | \n\t\t
\n\t\t\t Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0) \n\t\t\t | \n\t\t\t\n\t\t\t 1 July 2005 (2005-07-01) \n\t\t\t | \n\t\t\t\n\t\t\t 3 October 2011 (2011-10-03) \n\t\t\t | \n\t\t
Creative Commons Attribution 3.0 Unported (CC BY 3.0) | \n\t\t\t\n\t\t\t 5 October 2011 (2011-10-05) \n\t\t\t | \n\t\t\tCurrently | \n\t\t
The CC BY 3.0 license permits Works to be freely shared in any medium or format, as well as the reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as the source Work is cited and its Authors are acknowledged in the following manner:
\n\nContent reuse:
\n\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\n\nContent adaptation & reuse:
\n\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\n\nReposting & sharing:
\n\nOriginally published in {full citation}. Available from: {DOI}
\n\nRepublishing – More about Attribution Policy can be found here.
\n\nThe same principles apply to Works published under the CC BY-NC-SA 3.0 license, with the caveats that (1) the content may not be used for commercial purposes, and (2) derivative works building on this content must be distributed under the same license. The restrictions contained in these license terms may, however, be waived by the copyright holder(s). Users wishing to circumvent any of the license terms are required to obtain explicit permission to do so from the copyright holder(s).
\n\nDISCLAIMER: Neither the CC BY 3.0 license, nor any other license IntechOpen currently uses or has used before, applies to figures and tables reproduced from other works, as they may be subject to different terms of reuse. In such cases, if the copyright holder is not noted in the source of a figure or table, it is the responsibility of the User to investigate and determine the exact copyright status of any information utilised. Users requiring assistance in that regard are welcome to send an inquiry to permissions@intechopen.com.
\n\nAll rights to Books and all other compilations published on the IntechOpen platform and in print are reserved by IntechOpen.
\n\nThe copyright to Books and other compilations is subject to separate copyright from those that exist in the included Works.
\n\nAll Long Form Monographs/Compacts are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license granted to all others.
\n\nCopyright to the individual Works (Chapters) belongs to their specific Authors, subject to an agreement with IntechOpen and the Creative Common license granted to all others to:
\n\nUnder the following terms:
\n\nThere must be an Attribution, giving appropriate credit, provision of a link to the license, and indication if any changes were made.
\n\nNonCommercial - The use of the material for commercial purposes is prohibited. Commercial rights are reserved to IntechOpen or its licensees.
\n\nNo additional restrictions that apply legal terms or technological measures that restrict others from doing anything the license permits are allowed.
\n\nThe CC BY-NC 4.0 license permits Works to be freely shared in any medium or format, as well as reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as it is not used for commercial purposes. The source Work must be cited and its Authors acknowledged in the following manner:
\n\nContent reuse:
\n\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\n\nContent adaptation & reuse:
\n\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\n\nReposting & sharing:
\n\nOriginally published in {full citation}. Available from: {DOI}
\n\nAll Book cover design elements, as well as Video image graphics are subject to copyright by IntechOpen.
\n\nEvery reproduction of a front cover image must be accompanied by an appropriate Copyright Notice displayed adjacent to the image. The exact Copyright Notice depends on who the Author of a particular cover image is. Users wishing to reproduce cover images should contact permissions@intechopen.com.
\n\nAll Video Lectures under IntechOpen's production are subject to copyright and are property of IntechOpen, unless defined otherwise, and are licensed under the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This grants all others the right to:
\n\nShare — copy and redistribute the material in any medium or format
\n\nUnder the following terms:
\n\nUsers wishing to repost and share the Video Lectures are welcome to do so as long as they acknowledge the source in the following manner:
\n\n© {year} IntechOpen. Published under CC BY-NC-ND 4.0 license. Available from: {DOI}
\n\nUsers wishing to reuse, modify, or adapt the Video Lectures in a way not permitted by the license are welcome to contact us at permissions@intechopen.com to discuss waiving particular license terms.
\n\nAll software used on the IntechOpen platform, any used during the publishing process, and the copyright in the code constituting such software, is the property of IntechOpen or its software suppliers. As such, it may not be downloaded or copied without permission.
\n\nUnless otherwise indicated, all IntechOpen websites are the property of IntechOpen.
\n\nAll content included on IntechOpen Websites not forming part of contributed materials (such as text, images, logos, graphics, design elements, videos, sounds, pictures, trademarks, etc.), are subject to copyright and are property of, or licensed to, IntechOpen. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance of the content on this site is strictly prohibited.
\n\nPolicy last updated: 2016-06-08
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5239},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15810}],offset:12,limit:12,total:118377},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"10231",title:"Proton Therapy",subtitle:null,isOpenForSubmission:!0,hash:"f4a9009287953c8d1d89f0fa9b7597b0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10231.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10652",title:"Visual Object Tracking",subtitle:null,isOpenForSubmission:!0,hash:"96f3ee634a7ba49fa195e50475412af4",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10653",title:"Optimization Algorithms",subtitle:null,isOpenForSubmission:!0,hash:"753812dbb9a6f6b57645431063114f6c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10653.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10655",title:"Motion Planning",subtitle:null,isOpenForSubmission:!0,hash:"809b5e290cf2dade9e7e0a5ae0ef3df0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10655.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10657",title:"Service Robots",subtitle:null,isOpenForSubmission:!0,hash:"5f81b9eea6eb3f9af984031b7af35588",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10657.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10662",title:"Pedagogy",subtitle:null,isOpenForSubmission:!0,hash:"c858e1c6fb878d3b895acbacec624576",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10662.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10673",title:"The Psychology of Trust",subtitle:null,isOpenForSubmission:!0,hash:"1f6cac41fd145f718ac0866264499cc8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10673.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10675",title:"Hydrostatics",subtitle:null,isOpenForSubmission:!0,hash:"c86c2fa9f835d4ad5e7efd8b01921866",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10675.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Topology",subtitle:null,isOpenForSubmission:!0,hash:"85eac84b173d785f989522397616124e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10678",title:"Biostatistics",subtitle:null,isOpenForSubmission:!0,hash:"f63db439474a574454a66894db8b394c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10678.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10679",title:"Mass Production",subtitle:null,isOpenForSubmission:!0,hash:"2dae91102099b1a07be1a36a68852829",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10679.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10689",title:"Risk Management in Construction",subtitle:null,isOpenForSubmission:!0,hash:"e3805b3d2fceb9d33e1fa805687cd296",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10689.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:18},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:20},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:202},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5249},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"166",title:"Statistics",slug:"mathematics-statistics",parent:{title:"Mathematics",slug:"mathematics"},numberOfBooks:10,numberOfAuthorsAndEditors:148,numberOfWosCitations:86,numberOfCrossrefCitations:93,numberOfDimensionsCitations:161,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"mathematics-statistics",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9218",title:"Bayesian Inference on Complicated Data",subtitle:null,isOpenForSubmission:!1,hash:"5cf83c23db5b0ae47192d34ec8091162",slug:"bayesian-inference-on-complicated-data",bookSignature:"Niansheng Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9218.jpg",editedByType:"Edited by",editors:[{id:"221831",title:"Prof.",name:"Niansheng",middleName:null,surname:"Tang",slug:"niansheng-tang",fullName:"Niansheng Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7680",title:"Statistical Methodologies",subtitle:null,isOpenForSubmission:!1,hash:"b9ba6b053350f5e59925bce32b1d692d",slug:"statistical-methodologies",bookSignature:"Jan Peter Hessling",coverURL:"https://cdn.intechopen.com/books/images_new/7680.jpg",editedByType:"Edited by",editors:[{id:"20815",title:"Dr.",name:"Jan Peter",middleName:null,surname:"Hessling",slug:"jan-peter-hessling",fullName:"Jan Peter Hessling"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7372",title:"Bayesian Networks",subtitle:"Advances and Novel Applications",isOpenForSubmission:!1,hash:"ee81401d110a5f6bca2997a28e8d169b",slug:"bayesian-networks-advances-and-novel-applications",bookSignature:"Douglas McNair",coverURL:"https://cdn.intechopen.com/books/images_new/7372.jpg",editedByType:"Edited by",editors:[{id:"219757",title:"Dr.",name:"Douglas",middleName:null,surname:"McNair",slug:"douglas-mcnair",fullName:"Douglas McNair"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8362",title:"Time Series Analysis",subtitle:"Data, Methods, and Applications",isOpenForSubmission:!1,hash:"7e98dd03d921c19cc2324e91845d5160",slug:"time-series-analysis-data-methods-and-applications",bookSignature:"Chun-Kit Ngan",coverURL:"https://cdn.intechopen.com/books/images_new/8362.jpg",editedByType:"Edited by",editors:[{id:"227503",title:"Dr.",name:"Chun-Kit",middleName:null,surname:"Ngan",slug:"chun-kit-ngan",fullName:"Chun-Kit Ngan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6703",title:"Statistics",subtitle:"Growing Data Sets and Growing Demand for Statistics",isOpenForSubmission:!1,hash:"f67636870f28cdf080018abaddd953d2",slug:"statistics-growing-data-sets-and-growing-demand-for-statistics",bookSignature:"Türkmen Göksel",coverURL:"https://cdn.intechopen.com/books/images_new/6703.jpg",editedByType:"Edited by",editors:[{id:"190299",title:"Dr.",name:"Türkmen",middleName:null,surname:"Göksel",slug:"turkmen-goksel",fullName:"Türkmen Göksel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5856",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",subtitle:null,isOpenForSubmission:!1,hash:"950e8a681056d4b6bdc024121529d1ce",slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",bookSignature:"Valter Silva",coverURL:"https://cdn.intechopen.com/books/images_new/5856.jpg",editedByType:"Edited by",editors:[{id:"187136",title:"Dr.",name:"Valter",middleName:null,surname:"Silva",slug:"valter-silva",fullName:"Valter Silva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5964",title:"Bayesian Inference",subtitle:null,isOpenForSubmission:!1,hash:"b05b9b63cb02573c7e0cc5e877e35c61",slug:"bayesian-inference",bookSignature:"Javier Prieto Tejedor",coverURL:"https://cdn.intechopen.com/books/images_new/5964.jpg",editedByType:"Edited by",editors:[{id:"177972",title:"Dr.",name:"Javier Prieto",middleName:null,surname:"Tejedor",slug:"javier-prieto-tejedor",fullName:"Javier Prieto Tejedor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5446",title:"Advances in Statistical Methodologies and Their Application to Real Problems",subtitle:null,isOpenForSubmission:!1,hash:"93e5e8e7a09c351b3e0377d6ac6ccc35",slug:"advances-in-statistical-methodologies-and-their-application-to-real-problems",bookSignature:"Tsukasa Hokimoto",coverURL:"https://cdn.intechopen.com/books/images_new/5446.jpg",editedByType:"Edited by",editors:[{id:"69561",title:"Dr.",name:"Tsukasa",middleName:null,surname:"Hokimoto",slug:"tsukasa-hokimoto",fullName:"Tsukasa Hokimoto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3812",title:"Dynamic Programming and Bayesian Inference",subtitle:"Concepts and Applications",isOpenForSubmission:!1,hash:"f507023ddf3414519592ec0f0d6b25e3",slug:"dynamic-programming-and-bayesian-inference-concepts-and-applications",bookSignature:"Mohammad Saber Fallah Nezhad",coverURL:"https://cdn.intechopen.com/books/images_new/3812.jpg",editedByType:"Edited by",editors:[{id:"150393",title:"Dr.",name:"Mohammad Saber Fallah",middleName:null,surname:"Nezhad",slug:"mohammad-saber-fallah-nezhad",fullName:"Mohammad Saber Fallah Nezhad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2155",title:"Bayesian Networks",subtitle:null,isOpenForSubmission:!1,hash:"2c08ecbb5580e47a9c16cdaec48c2adc",slug:"bayesian-networks",bookSignature:"Wichian Premchaiswadi",coverURL:"https://cdn.intechopen.com/books/images_new/2155.jpg",editedByType:"Edited by",editors:[{id:"10820",title:"Dr.",name:"Wichian",middleName:null,surname:"Premchaiswadi",slug:"wichian-premchaiswadi",fullName:"Wichian Premchaiswadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:10,mostCitedChapters:[{id:"59209",doi:"10.5772/intechopen.73690",title:"Utilization of Response Surface Methodology in Optimization of Extraction of Plant Materials",slug:"utilization-of-response-surface-methodology-in-optimization-of-extraction-of-plant-materials",totalDownloads:3648,totalCrossrefCites:20,totalDimensionsCites:28,book:{slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",fullTitle:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes"},signatures:"Alev Yüksel Aydar",authors:[{id:"218870",title:"Dr.",name:"Alev Yüksel",middleName:null,surname:"Aydar",slug:"alev-yuksel-aydar",fullName:"Alev Yüksel Aydar"}]},{id:"56460",doi:"10.5772/intechopen.69501",title:"Application of Taguchi-Based Design of Experiments for Industrial Chemical Processes",slug:"application-of-taguchi-based-design-of-experiments-for-industrial-chemical-processes",totalDownloads:2134,totalCrossrefCites:9,totalDimensionsCites:21,book:{slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",fullTitle:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes"},signatures:"Rahul Davis and Pretesh John",authors:[{id:"199438",title:"Mr.",name:"Rahul",middleName:null,surname:"Davis",slug:"rahul-davis",fullName:"Rahul Davis"}]},{id:"64216",doi:"10.5772/intechopen.81170",title:"CNN Approaches for Time Series Classification",slug:"cnn-approaches-for-time-series-classification",totalDownloads:2607,totalCrossrefCites:8,totalDimensionsCites:12,book:{slug:"time-series-analysis-data-methods-and-applications",title:"Time Series Analysis",fullTitle:"Time Series Analysis - Data, Methods, and Applications"},signatures:"Lamyaa Sadouk",authors:[{id:"257943",title:"Ph.D.",name:"Lamyaa",middleName:null,surname:"Sadouk",slug:"lamyaa-sadouk",fullName:"Lamyaa Sadouk"}]}],mostDownloadedChaptersLast30Days:[{id:"59209",title:"Utilization of Response Surface Methodology in Optimization of Extraction of Plant Materials",slug:"utilization-of-response-surface-methodology-in-optimization-of-extraction-of-plant-materials",totalDownloads:3659,totalCrossrefCites:20,totalDimensionsCites:28,book:{slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",fullTitle:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes"},signatures:"Alev Yüksel Aydar",authors:[{id:"218870",title:"Dr.",name:"Alev Yüksel",middleName:null,surname:"Aydar",slug:"alev-yuksel-aydar",fullName:"Alev Yüksel Aydar"}]},{id:"56460",title:"Application of Taguchi-Based Design of Experiments for Industrial Chemical Processes",slug:"application-of-taguchi-based-design-of-experiments-for-industrial-chemical-processes",totalDownloads:2142,totalCrossrefCites:9,totalDimensionsCites:21,book:{slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",fullTitle:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes"},signatures:"Rahul Davis and Pretesh John",authors:[{id:"199438",title:"Mr.",name:"Rahul",middleName:null,surname:"Davis",slug:"rahul-davis",fullName:"Rahul Davis"}]},{id:"56653",title:"Bayesian Hypothesis Testing: An Alternative to Null Hypothesis Significance Testing (NHST) in Psychology and Social Sciences",slug:"bayesian-hypothesis-testing-an-alternative-to-null-hypothesis-significance-testing-nhst-in-psycholog",totalDownloads:2607,totalCrossrefCites:7,totalDimensionsCites:8,book:{slug:"bayesian-inference",title:"Bayesian Inference",fullTitle:"Bayesian Inference"},signatures:"Alonso Ortega and Gorka Navarrete",authors:[{id:"203438",title:"Dr.",name:"Alonso",middleName:null,surname:"Ortega",slug:"alonso-ortega",fullName:"Alonso Ortega"},{id:"208842",title:"Dr.",name:"Gorka",middleName:null,surname:"Navarrete",slug:"gorka-navarrete",fullName:"Gorka Navarrete"}]},{id:"61268",title:"The Application of Discrete Choice Models in Transport",slug:"the-application-of-discrete-choice-models-in-transport",totalDownloads:995,totalCrossrefCites:1,totalDimensionsCites:0,book:{slug:"statistics-growing-data-sets-and-growing-demand-for-statistics",title:"Statistics",fullTitle:"Statistics - Growing Data Sets and Growing Demand for Statistics"},signatures:"Foued Aloulou",authors:null},{id:"71603",title:"A Brief Tour of Bayesian Sampling Methods",slug:"a-brief-tour-of-bayesian-sampling-methods",totalDownloads:376,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"bayesian-inference-on-complicated-data",title:"Bayesian Inference on Complicated Data",fullTitle:"Bayesian Inference on Complicated Data"},signatures:"Michelle Y. Wang and Trevor Park",authors:null},{id:"56066",title:"Development of Falling Film Heat Transfer Coefficient for Industrial Chemical Processes Evaporator Design",slug:"development-of-falling-film-heat-transfer-coefficient-for-industrial-chemical-processes-evaporator-d",totalDownloads:1400,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"statistical-approaches-with-emphasis-on-design-of-experiments-applied-to-chemical-processes",title:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes",fullTitle:"Statistical Approaches With Emphasis on Design of Experiments Applied to Chemical Processes"},signatures:"Muhammad Wakil Shahzad, Muhammad Burhan and Kim Choon\nNg",authors:[{id:"174208",title:"Dr.",name:"Muhammad Wakil",middleName:null,surname:"Shahzad",slug:"muhammad-wakil-shahzad",fullName:"Muhammad Wakil Shahzad"}]},{id:"35660",title:"Making a Predictive Diagnostic Model for Rangeland Management by Implementing a State and Transition Model Within a Bayesian Belief Network (Case Study: Ghom- Iran)",slug:"making-a-predictive-diagnostic-model-for-rangeland-management-by-implementing-a-state-and-transition",totalDownloads:1992,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"bayesian-networks",title:"Bayesian Networks",fullTitle:"Bayesian Networks"},signatures:"Hossein Bashari",authors:[{id:"10124",title:"Dr.",name:"Hossein",middleName:null,surname:"Bashari",slug:"hossein-bashari",fullName:"Hossein Bashari"}]},{id:"64216",title:"CNN Approaches for Time Series Classification",slug:"cnn-approaches-for-time-series-classification",totalDownloads:2611,totalCrossrefCites:8,totalDimensionsCites:12,book:{slug:"time-series-analysis-data-methods-and-applications",title:"Time Series Analysis",fullTitle:"Time Series Analysis - Data, Methods, and Applications"},signatures:"Lamyaa Sadouk",authors:[{id:"257943",title:"Ph.D.",name:"Lamyaa",middleName:null,surname:"Sadouk",slug:"lamyaa-sadouk",fullName:"Lamyaa Sadouk"}]},{id:"54071",title:"Validation of Instrument Measuring Continuous Variable in Medicine",slug:"validation-of-instrument-measuring-continuous-variable-in-medicine",totalDownloads:1402,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"advances-in-statistical-methodologies-and-their-application-to-real-problems",title:"Advances in Statistical Methodologies and Their Application to Real Problems",fullTitle:"Advances in Statistical Methodologies and Their Application to Real Problems"},signatures:"Rafdzah Zaki",authors:[{id:"190238",title:"Dr.",name:"Rafdzah",middleName:null,surname:"Zaki",slug:"rafdzah-zaki",fullName:"Rafdzah Zaki"}]},{id:"68138",title:"Bayesian Graphical Model Application for Monetary Policy and Macroeconomic Performance in Nigeria",slug:"bayesian-graphical-model-application-for-monetary-policy-and-macroeconomic-performance-in-nigeria",totalDownloads:490,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"bayesian-networks-advances-and-novel-applications",title:"Bayesian Networks",fullTitle:"Bayesian Networks - Advances and Novel Applications"},signatures:"David Oluseun Olayungbo",authors:null}],onlineFirstChaptersFilter:{topicSlug:"mathematics-statistics",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/172981/tomoyuki-kawase",hash:"",query:{},params:{id:"172981",slug:"tomoyuki-kawase"},fullPath:"/profiles/172981/tomoyuki-kawase",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()